

Professor LORENZO CALO'

PUBBLICAZIONI

LAVORI PUBBLICATI SU RIVISTE INTERNAZIONALI

1. CALO' L, S.Cantaro, L.Bertazzo, A.Vianello, L.Vido and A.Borsatti. Synthesis and catabolism of PGE2 by a nephroblastoma associated with hypercalcemia without bone metastases. **Cancer** 1984; 54, 635-637.
2. CALO' L, S.Cantaro, A.Piccoli, A.Vianello, A.Borsatti, R.Bardini and A.Antonello. Interaction between Muzolimine, PGE2 and the renin- angiotensin -aldosterone system. **Z. Kardiol.**, 1985; 74, suppl. 2, 157-160.
3. V.Bettini, CALO' L, S.Cantaro, R.Martino, L.Munari, E.Selvatico, P.Ton. Liberation of prostaglandin- like substances from the isolated coronary artery in presence of angiotensin and 4-Methylesculetin. **Acta Vitaminol.Enzymol.**, 1985; 7 (3-4), 257-268.
4. S.Cantaro, CALO' L, A.Vianello, S.Favaro, G.P.Rossi and A.Borsatti. Platelet calmodulin concentration and phospholipase A2 activity in essential hypertension. **Regulatory Peptides**, 1985; Suppl. 4, 144-147.
5. L.Vido, M.Carli, G.F.Rizzoni, CALO' L, P.Dalla Palma, A.Parenti and A.Fusco. Congenital mesoblastic nephroma with hypercalcemia. Pathogenetic role of prostaglandins. **Am. J. Pediatr. Ematol. Oncol.**, 1986; 8: 149-155.
6. R. Vettor, C.De Palo, CALO' L, E.De Carlo, N.Sicolo, C.Martini and G.Federspil. Effect of exercise on plasma kallikrein and muscular phospholipase A2 activity in rats. **Mol. Cell. Endocrinol.**, 1986; 45: 65-70.
7. CALO' L, S.Cantaro, A.Vianello, L.Vido, G.F.Rizzoni and A.Borsatti. Arachidonic acid metabolites in a nephroblastoma associated with paraneoplastic hypercalcemia. **Prostaglandins**, 1986; 32 n.l, 116-120.
8. CALO' L, S.Cantaro, A.Vianello, S.Favaro and A.Borsatti. Platelet calmodulin concentration in essential hypertension and in Bartter's syndrome. **Am. J. Nephrol.** 1986; 6 Suppl.1, 60-62.
9. CALO' L, S.Cantaro, F.Di Virgilio, S.Favaro and A.Borsatti. Altered free cytosolic Ca²⁺ changes in fMet-Leu-Phe-stimulated neutrophils from patients with Bartter's syndrome. **Ann. N.Y. Acad. Sci** 1986; 488, 527-529.
10. L.Punzi, E.Schiavon, CALO' L, V.Malatesta, R.Ramonda, N.Trombetta and P.F.Gambari. The effect of Pirprofen on the prostaglandins and cyclic nucleotides of synovial fluid in rheumatoid arthritis. **Curr. Ther. Res**, 1987; 42:190-194.
11. F.Di Virgilio, L.CALO', S.Cantaro, S.Favaro, A.Piccoli and A.Borsatti. Resting and stimulated cytosolic free calcium levels in neutrophils from patients with Bartter's syndrome. **Clinical Science** 1987; 72: 483-488.
12. A.Tasca, A.D'Angelo, F.Zattoni, P.Ferrarese, CALO' L, F.Bui, P.Cagnato. Short - term and stabilized effects of percutaneous nephrolithotomy on the kidney. **Eur. Urol.** 1988; 14: 120-122.
13. CALO' L, S.Cantaro, F.Marchini, S.Giannini, R.Castrignano, G.Gambaro, A.Antonello, B.Baggio, A.D'Angelo, H.Williams and A.Borsatti. Is hydrochlorothiazide-induced hypocalciuria due to inhibition of prostaglandin E2 synthesis ? **Clinical Science** 1990; 78, 321-325.
14. CALO' L, S.Cantaro, A.Piccoli, A.D'Angelo, S.Giannini, H.E.Williams, A.Borsatti. Effect of nifedipine on urinary excretion of calcium and calcium-controlling hormones in essential hypercalciuria. **Cardiovascular drugs and therapy**, 1990; 4:983-986.
15. L.Punzi, F.Schiavon, R.Ramonda, F.Cavasin, A.M.Spiazzi, CALO' L and S.Todesco. Calmodulin in synovial fluid. **Med.Sci.Res.** 1990; 18:605-606.

16. CALO' L, S.Cantaro, A.Piccoli, S.Favaro, L.Bonfante, A.Borsatti. Full pattern of urinary prostaglandins in Bartter's syndrome. **Nephron**, 1990; 56, 451- 452.
17. F.Antonucci, M.Bertolissi, CALO' L. Plasma endothelin and renal function during infrarenal aortic crossclamping and nifedipine infusion. **Lancet**, (Letter), 1990; 336:1449.
18. CALO' L, S.Cantaro, S.Favaro, M.Plebani and A.Borsatti. Urinary excretion of prostanoids during treatment with enalapril compared with captopril. **Curr. Ther. Res** 1991; 49/3, 376-382.
19. A.Piccoli, CALO' L, F.Modena, B.Rossi, S.Cantaro, C.D.Paleari, H.E.Williams and A.Borsatti. Prostaglandins and renal response to protein loading in normal and glomerulonephritic kidneys: effect of indomethacin and dipyridamole. **Curr. Ther. Res**, 1991; 49/4:1-14.
20. Borsatti A, Rombola G, Surian M, CALO L, Fabbris A, Vezzoli G, Calderaro V, Maschio G, Borghi L, Bazzato G, De Santo N, Williams HE, Marangella M, Colussi G, Caudarella R, Kassirer JP, Tasca A, Schena FP, D'Angelo A, Moracchiello P. Calcium-oxalate nephrolithiasis - defective oxalate transport. **Kidney Int** 1991; 39 (6):1283-1298.
21. S.Cantaro, CALO' L, A.Piccoli, F.Marchini, G.Gambaro, S.Favaro, H.E.Williams, A.Borsatti. Anomalous neutrophil inositol triphosphate production in idiopathic calcium oxalate nephrolithiasis. **Nephron** 1992; 61: 241-242.
22. R.Vettor, C.Martini, CALO' L, S.Cantaro, C.Macor, C.De Palo, N.Sicolo, C.Scandellari, G.Federspil. Increased muscular phospholipase A₂ activity in diabetic rats. **Diabete & Metabolisme** 1992; 18: 213-217.
23. T.R.Wandzilak, CALO' L, S.D'Andre, A.Borsatti, and H.E.Williams. Oxalate transport in cultured porcine renal epithelial cells. **Urol.Res**, 1992; 20: 341-345.
24. A.Fracasso, CALO' L, S.Landini, P.Morachiello, F.Righetto, F.Scanferla, P.Toffoletto, R.Genchi, D.Roncali, S.Cantaro, G.De Silvestro, G.Cavatton, M.Masiero, M.Plebani, A.Borsatti and G.Bazzato. Peritoneal sclerosis: role of plasticizers in stimulating interleukin-1 production. **Peritoneal Dialysis International** 1993; 13, suppl. 2, 517-519.
25. N.G.De Santo, CALO' L, S.Coppola, P.Anastasio, S.Cantaro, S.Favaro, G.Capasso, A.Borsatti. Renal prostaglandins and thromboxane A₂ lack a functional significance in the genesis of protein-induced glomerular hyperfiltration in human renal disease. **Nephron**, 1993; 63: 49-53.
26. CALO' L, A.Fracasso, S.Cantaro, E.Cozzi, G.De Silvestro, M.Plebani, G.Bazzato and A.Borsatti. Plasticizers induced mononuclear cells interleukin 1 production: implications with peritoneal sclerosis. **Clinical Nephrology** 1993; 40 n°1: 57.
27. A.Piccoli, F.Modena, CALO' L, S.Cantaro, A.Avogadro, G.Nardo, R.Cerutti. Reduction in urinary prostaglandin excretion in the premenstrual syndrome. **Journal of Reproductive Medicine** 1993; 38: 941-944.
28. S.Favaro, L.Bonfante, A.Giacomini, CALO' L, E.De Vivo, M.Schiavon, G.Morandi, M.Masiero, M.Mussap, A.Borsatti. Microhematuria associated with microproteinuria: an intriguing new clinical entity. **Clinical Nephrology** 1994; 41 n°1: 56.
29. N.G. De Santo, CALO' L, P.Anastasio, S.Coppola, S.Cantaro, S.Favaro, G.Capasso, A.Borsatti. Renal synthesis of prostaglandins and thromboxane has no causative role for protein-induced glomerular hyperfiltration in healthy humans. **Nephron** 1994; 66: 45-51.
30. CALO' L, S.Cantaro, M.Rizzolo, S.Favaro, A.Antonello, A.Borsatti. Endothelin and vascular reactivity in Bartter's syndrome. **Nephron** 1994; 66: 370-371.

31. CALO' L, A.Borsatti, S.Favaro, L.Rabinowitz. Kaliuresis in normal subjects following oral potassium intake without increased plasma potassium concentration. **Nephron** 1995; 69: 253-258.
32. CALO' L, S.Cantaro, A.Calabro', F.Piarulli, M.Rizzolo, S.Favaro, A.Antonello, G.Crepaldi, A.Borsatti. Endothelium-derived vasoactive substances in Bartter's syndrome. **Angiology**, 1995; 46(10): 905-913.
33. CALO' L, T.E.Wandzilak, P.A.Davis, A.Borsatti, H.E.Williams. Effect of second messenger systems on oxalate uptake in renal epithelial cells. **Urological Research** 1995; 23: 89-94.
34. CALO' L, A.D'Angelo, S.Cantaro, M.Rizzolo, S.Favaro, A.Antonello, A.Borsatti. Intracellular calcium signalling and vascular reactivity in Bartter's syndrome. **Nephron** 1996; 72:570-573.
35. CALO' L, A.D'Angelo, S.Cantaro, M.C.Bordin, S.Favaro, A.Antonello and A.Borsatti. Increased urinary $\text{NO}_2^-/\text{NO}_3^-$ and cyclic GMP levels in patients with Bartter's syndrome: relationship to vascular reactivity. **Am.J.Kidney Dis.**1996; 27 n. 6: 784-789.
36. F.Antonucci, CALO' L, M.Rizzolo, S.Cantaro, M.Bertolissi, M.Travaglini, O.Geatti, A. Borsatti, A.D'Angelo. Nifedipine can preserve renal function in patients submitted to aortic surgery with infrarenal crossclamping. **Nephron** 1996; 74:668-673.
37. S.Favaro, L.Bonfante, A.D'Angelo, A.Giacomini, M.Normanno, CALO' L, V.Bordin, D.Vianello, A.Meani, A.Antonello and A.Borsatti. Is the red-cell morphology really useful to detect the source of hematuria ? **Am.J.Nephrol** 1997; 17:172-175.
38. CALO L. In memory of professor Arturo Borsatti 1936-1995. **Am.J.Nephrol** 1997; 17:203.
39. CALO' L, R.Scognamiglio, S.Nistri, M.Palisi, M.Miorelli, F.Zerbo, S.Cantaro, A.Antonello, G.Fasoli, A.D'Angelo. Evidence of Myocardial dysfunction in Bartter's syndrome. **Am.J. Nephrol** 1997; 17: 124-127.
40. A.Antonello, L.Bonfante, V.Bordin, CALO' L, S.Favaro, M.Rippa-Bonati, A.D'Angelo. The Bursa of Hieronymus Fabrici D'Acquapendente: past and present of an anatomical structura. **Am.J.Nephrol**, 1997; 17: 248-251.
41. Avogaro A, Piarulli F, Valerio A, Miola M, Calveri M, Pavan P, Vicini P, Cobelli C, Tiengo A, CALO' L and Del Prato S. Forearm nitric oxide balance, vascular relaxation, and glucose metabolism in NIDDM patients. **Diabetes** 1997; 46:1040-1046.
42. D'Angelo A., CALO' L, S.Cantaro, S.Giannini. Calcitropic hormones and nephrolithiasis. **Min.Electr.Metab** 1997; 23:269-272.
43. CALO' L, M.C.Bordin, P.A.Davis, S.Cantaro, M.Milani, L.Gandolfi, S.Favaro, A.Antonello, U.Fagiolo, A.D'Angelo. Constitutive nitric oxide synthase gene expression in Bartter's and Gitelman's syndrome and its relationship to their vascular hyporesponsiveness. **Contrib. Nephrol** 1997; 122:193-195.
44. CALO' L, M.Felice, S.Cantaro, G.Ceolotto, A.Monari, A.Antonello and A.Semplicini. Inhibition of furosemide-sensitive cation transport and activation of sodium-lithium exchange by endogenous circulating factor(s) in Bartter's and Gitelman's syndromes. **J Hypertension** 1997; 15:1407-1413.
45. CALO' L, S.Cantaro, D.Paleari, D.Vianello, F.Zerbo, L.Bonfante, S.Favaro, A.Antonello, A.D'Angelo. Urinary NO_2^- and NO_3^- evaluation by an ion chromatography system. **Biomedical Chromatography** 1998; 12: 97-98.

46. CALO' L, M.Nobile, S.Giannini, S.Cantaro, L.Dalle Carbonare, L.Sartori, A.D'Angelo, G.Crepaldi. *Altered bone metabolism of idiopathic hypercalciuria: a possible role for nitric oxide.* **It. J. Min. & Electrol. Metab** 1998; 12:15-20.
47. Semplicini A and CALO' L. Reply to the correspondence: Cation transport in Bartter's syndrome. **J. Hypertension** 1998; 16: 550-551.
48. CALO' L, P.A.Davis, M.Milani, L.Gandolfi, S.Cantaro, A.D'Angelo, U.Fagiolo. Constitutive endothelial nitric oxide synthase (ecNOS) gene expression in human monocytes. **Angiology** 1998; 49: 419-422.
49. CALO' L, P.A. Davis, M.Milani, S.Cantaro, L.Bonfante, S.Favaro, A.D'Angelo. Bartter's syndrome and Gitelman's syndrome: two entities sharing the same abnormality of vascular reactivity. **Clinical Nephrology** 1998; 50: 65-67.
50. CALO' L, G. Sartore, A. Bassi, C. Basso, S.Bertocco, R. Marin, S. Zambon, S. Cantaro, A. D'Angelo, P.A. Davis, E. Manzato and G. Crepaldi. Reduced susceptibility of low density lipoprotein to oxidation in patients with overproduction of nitric oxide (Bartter's and Gitelman's syndrome). **J. Hypertension** 1998; 16: 1001-1004.
51. Cantaro S, Zara C, Battaglia P, Di Loreto P.L, CALO' L, D'Angelo A, and Theophilidis G. In vivo and in vitro neurotoxic action of plasma ultrafiltrate from uraemic patients. **Nephrol Dial Transpl** 1998; 13:2288-2293.
52. CALO' L, PA Davis, S Cantaro, L Bonfante, R Castrignano, G Carraro, A D'Angelo. Effect of Doxazosin in mild to moderate hypertensive patients with insulin-dependent diabetes mellitus. **Acta Diabetologica** 1998; 35:96-100.
53. L Punzi, L. CALO', F Schiavon, M Pianon, M Rosada, S Todesco. Condrocalcinosis is a feature of Gitelman's variant of Bartter's syndrome. A new look at the hypomagnesemia associated with calcium pyrophosphate dihydrate crystal deposition disease. **Rev. Rhum.** (Engl. Ed) 1998; 65(10):571-574.
54. Giannini S, Nobile M, Sartori L, CALO' L, Tasca A, Dalle Carbonare L, Ciuffreda M, D'Angelo A, Pagano F, Crepaldi G. Bone density and skeletal metabolism are altered in idiopathic hypercalciuria. **Clinical Nephrology** 1998; 50:94-100.
55. CALO' L, Davis PA, Rigotti P, Milani M, Cantaro S, Marchini F, D'Angelo A, Antonello A. ecNOS overexpression in CsA treated renal transplant patients. Implications for CsA induced hypertension. **Transplantation Proc** 1998; 30:2012-2013.
56. CALO' L, P. A. Davis, M. Milani, S. Cantaro, A. Antonello, S. Favaro, A. D'Angelo. Increased endothelial nitric oxide synthase mRNA level in Bartter's and Gitelman's syndrome. Relationship to vascular reactivity. **Clinical Nephrology** 1999; 1:10-17.
57. S.Giannini, M.Nobile, L.Sartori, L.Dalle Carbonare, M.Ciuffreda, P.Corrò, A.D'Angelo, CALO' L and G.Crepaldi. The acute effects of moderate dietary protein restriction in patients with idiopathic hypercalciuria and calcium nephrolithiasis. **Am. J Clin. Nutrition** 1999; 69:267-271.
58. A.Avogaro, CALO' L, F.Piarulli, M.Miola, S. de Kreutzemberg, A. Maran, A.Burlina, R.Mingardi, A.Tiengo and S. Del Prato. Effect of acute ketosis on the endothelial function of type 1 diabetic patients. The role of Nitric Oxide. **Diabetes** 1999; 48:391-397.
59. Eknoyan G, Antonello A, De Santo NG, CALO' L, Massry SG. On the progress in the history of Nephrology. **Am J Nephrol** 1999; 19: 99-100.

60. Bonfante L, CALO' L, D'Angelo A, Favaro S, Abaterusso C, Mennella G, Normanno M, Spinello M, Antonello A. Water and its effect when drunk cold. The physician's view (1576-1751). **Am J Nephrol** 1999; 19:182-184.
61. Antonello A, CALO' L, Bonfante L, Mennella G, Abaterusso C, Spinello M, Favaro S, D'Angelo A. Giovan Battista Morgagni, a pioneer of clinical nephrology. **Am J Nephrol** 1999; 19:222-225.
62. Davis PA and CALO' L. Is atherosclerosis a no NO state? **Circulation** 1999; 20:2709-2712.
63. Vigili de Kreutzenberg S, Crepaldi C, Marchetto S, CALO' L, Tiengo A, Del Prato S, and Avogaro A. Plasma free fatty acids and endothelium-dependent vasodilation: effect of chain-length and cyclooxygenase inhibition. **J Clin Endocrinol & Metab** 2000; 85:793-798.
64. CALO' L, S.Giannini, P.Bonvicini, M.Nobile, S.Cantaro, M.Plebani, A.Semplicini, A.D'Angelo and G.Crepaldi. Idiopathic hypercalciuria: O₂-/NO relationship and altered bone metabolism. **J Endocrinol Invest**. 2000; 23:78-83.
65. CALO' L, R.Castrignano, PA Davis, G.Carraro, E.Pagnin, S.Giannini, A.Semplicini and A.D'Angelo. Role of insulin-like growth factor-1 in primary osteoporosis: a correlative study. **J Endocrinol Invest** 2000; 23:223-227.
66. CALO' L, A Semplicini. Physiological relevance of nitric oxide-angiotensin II interplay in the cardiovascular system. **J Hypertension** 2000; 18:351-352.
67. D'Angelo A, CALO' L, S. Giannini, G. Carraro, L. Bonfante, M. Zaninotto, N. Perin, D. Di Landro, P. Rigotti, A. Antonello. Parathyroid hormone and bone metabolism in kidney transplanted patients. **Clinical Nephrology** 2000; 53 (4): Insert 19-22.
68. CALO' L, R Marcon, P Rigotti, E Pagnin, G Mennella, M Spinello, L Bonfante, S Cantaro, A D'Angelo, A Semplicini, A Antonello. Oxidative stress and nitric oxide system in post transplant hypertension. **Clinical Nephrology** 2000; 53 (4): Insert 6-7.
69. CALO' L, A.Semplicini, P.A. Davis, P.Bonvicini, S.Cantaro, P.Rigotti, A.D'Angelo, U.Livi, A.Antonello. Cyclosporin-induced endothelial dysfunction and hypertension: are nitric oxide system abnormality and oxidative stress involved? **Transplant Int** 2000; 13(Suppl.1): S413-S418.
70. Palatini P, Floreani M, Padrini R, Piccoli P, Bertoli M, CALO' L, and Orlando R. Effects of Chronic Renal Failure and Hemodialysis on the Monoethylglycinexylidide Liver Function Test. **Clin Chem** 2000; 46: 1406-1408.
71. CALO' L, L Punzi, A Semplicini. Hypomagnesemia and chondrocalcinosis in Bartter's and Gitelman's syndrome: review of the pathogenetic mechanisms. **Am J Nephrol** 2000; 20:347-350.
72. CALO' L, PA Davis and A Semplicini. Control of vascular tone in the syndromes of Bartter and Gitelman. **Crit Rev Clin Lab Sci** 2000; 37(6):503-522.
73. S.Cantaro, S.Milan Manani, R.Marcon, L.Bonfante, M.Masiero, A.D'Angelo, CALO' L. Urinary excretion of vasoactive substances in chronic renal failure. **Clinical Nephrology** 2001; 55:393-399.
74. CALO' L, Milani M, Pagnin E, Zaghetto F, Davis P, Piccin A, Costa R, Plebani M and Semplicini A. Analysis of Gq protein alpha subunit mRNA expression in human monocytes. Relevance of the purification step. **Clin Chim Acta** 2001; 309:13-18.
75. Bonfante L, Davis PA, Spinello M, Antonello A, D'Angelo A, Semplicini A, CALO' L. Chronic renal failure, end-stage renal disease, and peritoneal dialysis in gitelman's syndrome. **Am J Kidney Dis** 2001; 38:165-168.

76. CALO' L, Ceolotto G, Milani M, Pagnin E, van den Heuvel LP, Sartori M, Davis PA, Costa R, Semplicini A. Abnormalities of Gq-mediated cell signaling in Bartter and Gitelman syndrome. **Kidney Int** 2001; 60:882-889.
77. Burra P, Chirizzi L, Cardin R, Cadrobbi R, Baldan N, Calabrese F, Pettenazzo E, CALO' L, Plebani M, Rigotti P. Warm hepatic ischemia in pigs: effects of L-arginine and oligotide treatment. **J Invest Surg** 2001; 14:303-312.
78. Semplicini A, Maresca A, Sartori M, CALO' L, Pessina AC. Hypertension and cerebrovascular diseases: a specific role of vascular protection for the prevention of dementia. **J Cardiovasc Pharmacol**; 38 Suppl 2: S79-82, 2001.
79. CALO' L, Davis PA, Semplicini. Reduced content of alpha subunit of Gq protein content in monocytes of Bartter and Gitelman syndromes: Relationship with vascular hyporeactivity. **Kidney Int** 2002; 61:353-354.
80. Punzi L, CALO' L, Plebani M. Clinical significance of cytokine determination in synovial fluid. **Crit Rev Clin Lab Sci** 2002; 39(1):63-88.
81. CALO' L. Book review. **Cell Biol Int**, 2002; 26(6):573.
82. Antonello A, Bonfante L, Favaro S, Gambaro G, D'Angelo A, Mennella G, CALO' L. Hermann Boerhaave and Lithotomy: What He Thought about It. **Am J Nephrol** 2002; 22:290-294.
83. Iori E, CALO' L, Valbusa D, Ceolotto G, Milani M, Pengo V, De Kreutzenberg SV, Tiengo A, Avogaro A. Diabetic ketosis activates lymphomonocyte-inducible nitric oxide synthase. **Diabet Med** 2002; 19:777-783.
84. CALO' L, Giacon B, Davis PA, Pagnin E, Piccin A, Riegler P, Huber W, Antonello A and Semplicini A. Oxidative stress and TGF β in kidney-transplanted patients with cyclosporin-induced hypertension. Effect of carvedilol and nifedipine. **Clinical Nephrology** 2002; 56:103-110.
85. CALO' LA, Davis PA, Giacon B, Pagnin E, Sartori M, Riegler P, Antonello A, Huber W, Semplicini A. Oxidative stress in kidney transplant patients with calcineurin inhibitor-induced hypertension: effect of ramipril. **J Cardiovasc Pharmacol** 2002; 40(4):625-631.
86. Semplicini A, Ceolotto G, Sartori M, Maresca A, Baritono E, De Toni R, Paparella I, CALO' L. Regulation of glomerular filtration in essential hypertension: role of abnormal Na⁺ transport and atrial natriuretic peptide. **J Nephrol** 2002;15:489-496.
87. CALO' L, Marchini F, Davis PA, Rigotti P, Pagnin E, Semplicini A. Kidney transplant in Gitelman's syndrome. Report of the first case. **J Nephrol** 2003; 16:144-147.
88. Semplicini A, Sartori M, Ceolotto G, CALO' L. The Li/Na exchange in hypertension. **Frontiers in Biosciences** 2003; 8:d912-929.
89. Avogaro A, Pagnin E and CALO' L. Monocyte NADPH Oxidase Subunit p22(phox) and Inducible Hemeoxygenase-1 Gene Expressions Are Increased in Type II Diabetic Patients: Relationship with Oxidative Stress. **J Clin Endocrinol Metab** 2003; 88:1753-1759.
90. CALO' LA, Stanic L, Davis PA, Pagnin E, Munaretto G, Fusaro M, Landini S, Semplicini A, Piccoli A. Effect of Epoetin on HO-1 mRNA level and plasma antioxidants in hemodialysis patients. **Int J Clin Pharmacol Ther**, 2003; 41(5):187-192.
91. Scognamiglio R, Semplicini A and CALO' L. Myocardial function in Bartter's and Gitelman's syndromes. **Kidney Int** 2003; 64: 366-367.

92. CALO' L, Davis PA, Semplicini A. Bartter's/Gitelman's syndrome: a model for the relationships between hypertension, angiotensin II, oxidative stress and remodeling. **Clinical Nephrology** 2003; 59:393-394.
93. Armanini D, CALO' L, Semplicini A. Pseudohyperaldosteronisms: pathogenetic mechanisms. **Crit Rev Clin Lab Sci** 2003; 40(3):295-335.
94. CALO' L, Pagnin E, Davis PA, Sartori M and Semplicini A. Oxidative stress related factors in Bartter's and Gitelman's syndromes: relevance for angiotensin II signaling. **Nephrol Dial Transplant** 2003; 18:1518-1525.
95. Antonello A, D'Angelo A, Nalesso F, Capezzi M, Malagoli A, Pastori G, Lazzarin R, CALO' L, Bonfante L, Gambaro G. Double urine circulation: importance of pores. **J Nephrol** 2003; 16:958-960.
96. CALO' LA, Zaghetto F, Pagnin E, Davis PA, Semplicini A, Pessina AC. Effect of manidipine on gene expression and protein level of oxidative stress-related proteins: p22phox and HO-1: relevance for antihypertensive and anti-remodeling effects. **J Cardiovasc Pharmacol** 2004; 43:531-538.
97. Semplicini A, Benetton V, CALO' L, Realdi A, Mascagna V, Sartori M. Hypertension in Acute Ischemic Stroke: A Compensatory Mechanism or an Additional Damaging Factor? **Cardiovasc Rev Rep** 2004; 25:51-57.
98. Baritono E, Ceolotto G, Papparella I, Sartori M, Ciccariello L, Iori E, CALO' L, Pessina AC and Semplicini A. Abnormal regulation of G protein α_2 subunit in skin fibroblast from insulin-resistant hypertensive individuals. **J Hypertens** 2004; 22:783-792.
99. CALO' LA, Zaghetto F, Pagnin E, Davis PA, De Mozzi P, Sartorato P, Martire G, Fiore C, Armanini D. Effect of aldosterone and glycyrrhetic acid on the protein expression of PAI-1 and p22(phox) in human mononuclear leukocytes. **J Clin Endocrinol Metab** 2004; 89:1973-1976.
100. Sartori M, Ceolotto G, Papparella I, Baritono E, Ciccariello L, CALO' L, Leoni M, Semplicini A. Effects of angiotensin II and insulin on ERK1/2 activation in fibroblasts from hypertensive patients. **Am J Hypertension** 2004; 17:604-610.
101. Fiore C, CALO LA, Ragazzi E, Bielenberg J, Armanini D. Licorice from antiquity to the end of the 19th century: applications in medical therapy. **J Nephrol** 2004; 17:337-341.
102. CALO LA, Pagnin E, Davis PA, Sartori M, Ceolotto G, Pessina AC, Semplicini A. Increased expression of regulator of G protein signaling-2 (RGS-2) in Bartter's/Gitelman's syndrome. A role in the control of vascular tone and implication for hypertension. **J Clin Endocrinol Metab** 2004; 89:4153-4157.
103. Pagnin E, Davis PA, Sartori M, Semplicini A, Pessina AC, CALO LA. Rho kinase and PAI-1 in Bartter's/Gitelman's syndromes: relationship to angiotensin II signaling. **J Hypertens** 2004; 22(10):1963-1969.
104. CALO LA, Naso A, Pagnin E, Davis PA, Castoro M, Corradin R, Riegler P, Cascone C, Huber W, Piccoli A. Vitamin E-coated dialyzers reduce oxidative stress related proteins and markers in hemodialysis--a molecular biological approach. **Clinical Nephrology** 2004; 62(5):355-361.
105. Sartori M, Parotto M, Pagnin E, Cattelan F, Ceolotto G, Papparella I, Lenzini L, CALO' LA, Semplicini A. G-Protein β_3 -Subunit Gene C825T Polymorphism and Cardiovascular Risk. **High Blood Pressure & Cardiovascular Prevention** 2004; 11: 107-112.

106. Pagnin E, Fadini G, de Toni R, Tiengo A, CALO L, Avogaro A. Diabetes Induces p66shc Gene Expression in Human Peripheral Blood Mononuclear Cells: Relationship With Oxidative Stress. **J Clin Endocrinol Metab** 2005; 90:1130-1136.
107. CALO LA, Semplicini A, Davis PA. Antioxidant and antiinflammatory effect of carvedilol in mononuclear cells of hypertensive patients. **Am J Med** 2005; 118(2):201-202.
108. Armanini D, CALO LA. Aldosterone, inflammation, and preeclampsia. **Hypertension** 2005 Mar; :e10.
109. Semplicini A, CALO L. Administering antihypertensive drugs after acute ischemic stroke: timing is everything. **CMAJ** 2005; 172:625-626.
110. CALO LA, Davis PA, Pagnin E, Semplicini A, Pessina AC. NADPH oxidase, superoxide overproduction and nitric oxide bioavailability in essential hypertension. **J Hypertens** 2005; 23:665-666.
111. CALO LA, Pagnin E, Davis PA, Armanini D. Oxidative stress and profibrotic action of aldosterone. **Am J Hypertens** 2005; 18:441
112. Priante G, Musacchio E, Pagnin E, CALO LA, Baggio B. Specific effect of arachidonic acid on inducible nitric oxide synthase mRNA expression in human osteoblastic cells. **Clin Sci (Lond)** 2005; 109:177-182.
113. Semplicini A, CALO' LA. Choice of antihypertensives after acute ischemic stroke- Response. **CMAJ** 2005, 173:340.
114. CALO' LA, Pagnin E, Davis PA, Sartori M, Semplicini A, Pessina AC. Rho kinase inhibition and vascular protection: support from studies in Bartter and Gitelman syndrome. **Arterioscler Thromb Vasc Biol** 2005; 25(4):e34.
115. CALO' LA, Pagnin E, Sartori M, Semplicini A, Pessina AC. Bartter's and Gitelman's syndromes: a confirm in humans of the utility of Rho kinase inhibition for cardiovascular protection. **J Hypertens** 2005; 23:1273-1275.
116. CALO' LA, Pessina AC, Semplicini A. Angiotensin II signaling in the Bartter's and Gitelman's syndromes, a negative human model of hypertension. **High Blood Pressure & Cardiovascular Prevention** 2005; 12:17-26.
117. CALO' LA, Davis PA, Semplicini A, Pessina AC. L-carnitine and erythropoiesis: relationship with heme oxygenase-1. **Nephrol, Dial, Transplant** 2005; 20:1769-1770.
118. Pagnin E, Semplicini A, Sartori M, Pessina AC and CALO' LA. Reduced mRNA and protein content of Rho guanine nucleotide exchange factor (RhoGEF) in Bartter's and Gitelman's syndromes. Relevance for the pathophysiology of hypertension. **Am J Hyperten** 2005; 18:1200-1205.
119. CALO' LA and Armanini D. Aldosterone-mediated endothelial remodeling and oxidative stress. **Kidney Int** 2005; 68:1899.
120. CALO' LA, Pagnin E, Davis PA, Semplicini A, Nicolai R, Calvani M and Pessina AC. Antioxidant effect of L-carnitine and its short chain esters. Relevance for the protection from oxidative stress related cardiovascular damage. **Int J Cardiol** 2006; 107: 54-60.
121. CALO' LA, Pagnin E, Davis PA, Loddo M, Mian C, Semplicini A, Pycha A. Effect of doxazosin on oxidative stress related proteins in benign prostatic hyperplasia. **Urol Int** 2006; 76:36-41.

122. Armanini D, Fiore C and CALO LA. Mononuclear Leukocyte Mineralocorticoid Receptors. A Possible Link Between Aldosterone and Atherosclerosis. **Hypertension** 2006; 47; e4.
123. CALO' LA, L Bertipaglia, E Pagnin, PA Davis, M Sartori, A Semplicini and AC Pessina. Effect of doxazosin on oxidative stress related proteins in essential hypertensive patients. **Clin Exp Hypertens** 2006; 28:181-188.
124. Davis PA, Valacchi G, Pagnin E, Shao Q, Gross HB, CALO' L, Yokoyama W. Walnuts reduce aortic ET-1 mRNA levels in hamsters fed a high fat, atherogenic diet. **J Nutr** 2006; 136:428-432.
125. Davis PA, Pagnin E, Semplicini A, Avogaro A and CALO' LA Insulin signaling, glucose metabolism and the angiotensin II signaling system. Studies in Bartter's/Gitelman's syndromes. **Diabetes Care** 2006; 29:469-471.
126. Sartori M, Ceolotto G, Papparella I, Lenzini L, Leoni M, CALO LA, Semplicini A. Galphai2 expression, hypertension and insulin resistance. **J Hypertens** 2006; 24:785.
127. CALO' LA, Davis PA, Piccoli A, Pessina AC. A role for heme oxygenase-1 in the antioxidant and antiapoptotic effect of erythropoietin. The start of a good news/bad news story? **Nephron Physiology** 2006; 103:107-111.
128. CALO' LA. Vascular tone control in humans: the utility of studies in Bartter's/Gitelman's syndromes. **Kidney Int** 2006; 69:963-966.
129. Sartori M, CALO' LA, Mascagna V, Realdi A, Macchini L, Ciccariello L, De Toni R, Cattelan F, Pessina AC and Semplicini A. Aldosterone and refractory hypertension: a prospective cohort study. **Am J Hyperten** 2006; 19:373-379.
130. Davis PA, Mussap M, Pagnin E, Bertipaglia L, Savica V, Semplicini A and CALO' LA. Early markers of inflammation in a high angiotensin II state. Results of studies in Bartter's/Gitelman's syndromes. **Nephrol, Dial, Transpl**, 2006, 21:1697-1701.
131. CALO LA, Cosentino F, De Luca N. Metabolic syndrome: current issues and perspectives. **Panminerva Med** 2006; 48:1-2.
132. Pagnin E, Davis PA, Semplicini A, CALO LA. The search for a link between inflammation and hypertension--contribution from Bartter's/Gitelman's syndromes. **Nephrol Dial Transplant**. 2006; 21:2340-2342.
133. CALO' LA, Pagnin E, Mussap M, Davis PA, Semplicini A. Rho/Rho-kinase and C-reactive protein relationship in hypertension and atherosclerosis. **Nephrol Dial Transplant**. 2006; 21:1131-1132.
134. Semplicini A, Lenzini L, Sartori M, Papparella I, CALO' LA, Pagnin E, Strapazzon G, Benna C, Costa R, Avogaro A, Ceolotto G, Pessina AC. Reduced expression of regulator of G-protein signaling 2 (RGS2) in hypertensive patients increases calcium mobilization and ERK1/2 phosphorylation induced by angiotensin II. **J Hypertens**. 2006; 24:1125-1135.
135. CALO LA. 'The Heart Never Grows Better by "AGE"; I Fear Rather Worse...'. Philip Stanhope, 4th Earl of Chesterfield. **Blood Purif**. 2006; 24:367-368
136. Savica V, CALO' LA, Monardo P, Santoro D, Bellinghieri G. Phosphate binders and management of hyperphosphataemia in end-stage renal disease. **Nephrol Dial Transplant** 2006; 21:2065-2068.
137. Sartori M, Benetton V, Carraro AM, CALO LA, Macchini L, Giantin V, Tosato F, Pessina AC, Semplicini A. Blood pressure in acute ischemic stroke and mortality: a study with noninvasive blood pressure monitoring. **Blood Press Monit**. 2006,11:199-205.

138. Semplicini A, Benetton V, Mascagna V, Macchini L, Realdi A, Sartori M, CALO L. Problems related to short-term antihypertensive therapy in acute ischemic stroke. **Clin Exp Hypertens**. 2006; 28:327-334.
139. CALO' LA, Dall'Amico R, Pagnin E, Bertipaglia L, Zacchello G, Davis PA. Oxidative stress and post-transplant hypertension in pediatric kidney-transplanted patients. **J. Pediatr**. 2006; 149: 53-57.
140. Fiore C, CALO LA, Colombo L, Grimm CE, Armanini D. History of aldosterone on its 50th birthday. **J Nephrol**. 2006; 19 Suppl 10:S124-126.
141. Fiore C, Sticchi D, Pellati D, Forzan S, Bonanni G, Bertoldo A, Massironi M, CALO L, Fassina A, Rossi GP, Armanini D. Identification of the mineralocorticoid receptor in human spermatozoa. **Int J Mol Med**. 2006;18:649-652.
142. CALO LA, Armanini D. Aldosterone and thrombosis formation: Implications for ischemic and atherosclerotic heart disease. **J Endocrinol Invest**. 2006;29:675-676.
143. Davis PA, CALO' LA. Carnitine'S protective effect on oxidative stress is mediated by heme oxygenase-1. **Nephrology** (Carlton). 2006, 11:569.
144. Savica V, CALO' LA, Caldarera R, Cavaleri A, Granata A, Santoro D, Savica R, Muraca U, Mallamace A, Bellinghieri G. Phosphate salivary secretion in hemodialysis patients: implications for the treatment of hyperphosphatemia. **Nephron Physiol**. 2007, 105:52-55
145. CALO' LA, Pessina AC. RhoA/Rho-kinase pathway: much more than just a modulation of vascular tone. Evidence from studies in humans. **J Hypertens**. 2007; 25:259-264.
146. CALO' LA, Naso A, Carraro G, Wratten ML, Pagnin E, Bertipaglia L, Rebeschini M, Davis PA, Piccoli A, Cascone C. Effect of haemodiafiltration with online regeneration of ultrafiltrate on oxidative stress in dialysis patients. **Nephrol Dial Transplant**. 2007, 22: 1413 - 1419
147. Sartori M, Parotto E, Bonso E, Semplicini A, Palatini P, Pessina AC, CALO' LA. Autonomic nervous system function in chronic hypotension associated with Bartter and Gitelman syndromes. **Am J Kidney Dis**. 2007; 49:330-335.
148. Scognamiglio R, Negut C, CALO' LA. Aborted sudden cardiac death in two patients with Bartter's/Gitelman's syndromes. **Clinical Nephrology** 2007; 67:193-197.
149. CALO' LA, Davis PA. NADPH oxidase subunits (NOX-1, p22phox, Rac-1) and tacrolimus-induced nephrotoxicity in a rat renal transplant model. **Nephrol Dial Transplant**. 2007; 22: 2402
150. CALO' LA, Davis PA, Palatini P, Semplicini A, Pessina AC. Urinary albumin excretion, endothelial dysfunction and cardiovascular risk: study in Bartter's/Gitelman's syndromes and relevance for hypertension. **J Hum Hypertens**. 2007; 21:904-906
151. Savica V, CALO' LA, Granata A, Caldarera R, Cavaleri A, Santoro D, Monardo P, Savica R, Muraca U, Bellinghieri G. A new approach to the evaluation of hyperphosphatemia in chronic kidney disease. **Clinical Nephrology** 2007; 68:216-221.
152. CALO' LA, Davis PA, Pagnin E, Schiavo S, Semplicini A, Pessina AC. Linking inflammation and hypertension in humans: studies in Bartter's/Gitelman's syndrome patients. **J Hum Hypertens**. 2008; 22: 223-225.
153. Savica V, CALO' L, Santoro D, Monardo P, Granata A, Bellinghieri G. Salivary phosphate secretion in chronic kidney disease. **J Ren Nutr**. 2008;18:87-90.

154. Iori E, Pagnin E, Gallo A, CALÒ' L, Murphy E, Ostuni F, Fadini GP, Avogaro A. Heme oxygenase-1 is an important modulator in limiting glucose-induced apoptosis in human umbilical vein endothelial cells. **Life Sci.** 2008; 82: 383-392.
155. Savica V, CALO' LA, Davis PA, Bellinghieri G. Hyperphosphoremia in kidney failure- salivare phosphate as a marker and possibile target. **Clinical Nephrology** 2008, 69:229.
156. Sartori M, Cosenzi A, Bernobich E, CALO' LA, Bellini G, Semplicini A. A pheochromocytoma with normal clonidine-suppression test: how difficult the biochemical diagnosis? **Intern Emerg Med.** 2008; 3: 61-64
157. CALO' LA, Davis PA, Pagnin E, Bertipaglia L, Naso A, Piccoli A, Corradini R, Spinello M, Savica V, Libera L. Carnitine-Mediated Improved Response to Erythropoetin Involves Induction of Haem Coxygenase-1: Studies in Humans and in an Animal Model. **Nephrol Dial Transplant.** 2008 23: 890-895
158. CALO' LA, Pagnin E, Ceolotto G, Davis PA, Schiavo S, Papparella I, Semplicini A, Pessina AC. Silencing regulator of G protein signaling-2 (RGS-2) increases angiotensin II signaling: insights into hypertension from findings in Bartter's/Gitelman's syndromes. **J Hypertens.** 2008; 26:938-945.
159. CALO' LA, Puato M, Schiavo S, Zanardo M, Tirrito C, Pagnin E, Balbi G, Davis PA, Palatini P, Pauletto P. Absence of vascular remodelling in a high angiotensin-II state (Bartter's and Gitelman's syndromes): implications for angiotensin II signalling pathways. **Nephrol Dial Transplant.** 2008; 23:2804-2809.
160. Savica V, CALO' LA, Monardo P, Caldarera R, Cavaleri A, Santoro D, Mallamace A, Bellinghieri G, Muraca U. High phosphate content beverages in dialysis patients: Relevance for hyperphosphatemia and cardiovascular risk. **Nutr Metab Cardiovasc Dis.** 2008; 18:e39-40.
161. Semplicini A, Benetton V, Macchini L, Realdi A, Manara R, Crollo C, Parotto E, Mascagna V, Leoni M, CALO' LA, Pessina AC, Tosato F. Intravenous thrombolysis in the emergency department for the treatment of acute ischaemic stroke. **Emerg Med J** 2008; 25:403-406.
162. CALO' LA and Davis PA. EPO induces rise in serum ADMA but does not prevent the increase in NO release: the likely involvement of HO-1. **Nephrol Dial Transplant** 2008; 23:3035-3036.
163. Scognamiglio R, CALO' LA, Negut C, Coccato M, Mormino P, Pessina AC. Myocardial perfusion defects in Bartter and Gitelman syndromes. **Eur J Clin Invest.** 2008; 38:888-895.
164. Realdi A, Favaro A, Santonastaso P, Nuti M, Parotto E, Inverso G, Leoni M, Macchini L, Vettore F, CALO L, Semplicini A. Obsessive-Compulsive and Post Traumatic Avoidance Symptoms Influence the Response to Antihypertensive Therapy: Relevance in Uncontrolled Hypertension. **Pharmaceuticals** (Basel). 2009; 2:82-93.
165. Savica V, CALO' LA, Monardo P, Davis PA, Granata A, Santoro D, Savica R, Musolino R, Comelli MC, Bellinghieri G. Salivary Phosphate-Binding Chewing Gum Reduces Hyperphosphatemia in Dialysis Patients. **J Am Soc Nephrol.** 2009; 20:639-644.
166. Savica V, CALO' LA, Monardo P, Santoro D, Mallamace A, Muraca U, Bellinghieri G. Salivary phosphorus and phosphate content of beverages: implications for the treatment of uremic hyperphosphatemia. **J Ren Nutr.** 2009;19:69-72.
167. Davis PA, Mormino P and CALO' LA. Erythropoietin, heme oxygenase-1 and vascular tissue protective effects. **Clinical Nephrology** 2009, 71:365-366.
168. Davis PA, Mormino P, Savica E and CALO' LA. L-Carnitine, inflammation and hypertension. **Nephrology** 2009; 14:264-265.

169. CALO' LA, Naso A, PA Davis. Hemodiafiltration and oxidative stress in dialysis patients. **Blood Purification** 2009; 28:59-60.
170. CALO' LA, Savica V, Davis PA. Phosphorus in excess: a 'nutrient pollution' problem in the blood-broken hearts like broken lakes (eutrophication)? **Eur J Clin Nutr** 2009; 63:1460.
171. Fiore C, Sartorato P, Pagnin E, Ragazzi E, CALO' LA, Armanini D. Effect of canrenone and amiloride on the prooxidative effect induced by aldosterone in human mononuclear leukocytes in vitro. **J Endocrinol Invest**, 2009, 32:895-898.
172. CALO' LA, Montisci R, Scognamiglio R, Davis PA, Pagnin E, Schiavo S, Mormino P, Semplicini A, Palatini P, D'Angelo A and Pessina AC. High angiotensin II state without cardiac remodeling (Bartter's and Gitelman's syndromes). Are angiotensin II type 2 receptors involved? **J Endocrinol Invest**, 2009; 32:832-836
173. Savica V, Bellinghieri G and CALO' LA. Association of serum phosphorus concentration with cardiovascular risk. **Am J Kidney Dis** 2009; 54(2):389.
174. CALO' LA. Revisiting Essential Hypertension- a "mechanism-based" approach may argue for a better definition of hypertension. **Clinical Nephrology** 2009, 72:83-86.
175. Savica V, Bellinghieri G, CALO' LA. Salivary glands: a 'third kidney' for phosphate excretion in kidney disease? **Blood Purif.** 2009; 28:364.
176. Francini-Pesenti F, CALO' LA, Fiore C, Mormino P, Savica V, Davis PA. Diet and the kidney. **J Nephrol** 2009; 22 Suppl 14:139-142.
177. Savica V, Santoro D, Mallamace A, Monardo P, Davis PA, CALO' LA, Li Vecchi M, Muraca U, Bellinghieri G. Phosphorus: the philosopher's stone discovered in 1669. **J Nephrol** 2009; 22 Suppl 14:60-63.
178. CALO' LA, Pagnin E, Davis PA, Armanini D, Formino P, Rossi GP and Pessina AC. Oxidative stress-related proteins in a Conn's adenoma tissue. Relevance for aldosterone's prooxidative and proinflammatory activity. **J Endocrinol Invest**, 2010; 33:48-53.
179. CALO' LA, Schiavo S, Davis PA, Pagnin E, Mormino P, D'angelo A, Pessina AC. Angiotensin II signaling via type 2 receptors in a human model of vascular hyporeactivity: implications for hypertension. **J Hypertens**. 2010; 28:111-118.
180. CALO' LA, Davis PA. Propionyl-L-Carnitine, oxidative stress-mediated vascular disease and relevance of HO-1 induction. **Arterioscler Thromb Vasc Biol** 2010 e-letter 28 January 2010
181. Semplicini A, Strapazzon G, Papparella I, Sartori M, Realdi A, Macchini L, CALO' L, Ceolotto G. RGS2 expression and aldosterone: renin ratio modulate response to drug therapy in hypertensive patients. **J Hypertens** 2010; 28:1104-1108.
182. CALO' LA, Davis PA. The PGC1{alpha}-PPAR{delta}-HO-1 system: supporting evidence from studies in Bartter's/Gitelman's syndromes. **Cardiovasc Res**. 2010; 86:535.
183. Strapazzon G, Piccoli A, CALO' LA. Comment on: Acute kidney injury and rhabdomyolysis: a role for the regulator of G protein signaling (RGS)-2? **Renal Failure** 2010; 32:529-530.
184. Davis PA, Savica V, CALO' LA. PHOS-FAKE or PHOS-FATAL- Does intake of phosphate from foods lead to elevated plasma phosphate and its associated cardiovascular risks?. **Clinical Nephrology**, 2010; 74:1-3.
185. Pengo MF and CALO' LA. A rare cause of flank pain. **NDT Plus** 2010; 3: 316-317.

186. CALO' LA, Schiavo S, Davis PA, Pagnin E, Mormino P, D'Angelo A, Pessina AC. ACE2 and angiotensin 1-7 are increased in a human model of cardiovascular hyporeactivity: Pathophysiological implications. **J Nephrol** 2010; 23:472-477.
187. Savica V, Santoro D, CALO' LA. Hemodiafiltration in a critical dialysis patient with H1N1 influenza A. **Renal Failure** 2010; 2010; 32:902.
188. Anderwald C, Ankersmit HJ, Badaoui A, Beneduce L, Buko VU, CALO' LA, et al. Research update for articles published in EJCI in 2008. **Eur J Clin Invest.** 2010; 40:770-789.
189. CALO' LA, Fusaro M, Davis PA. HO-1 attenuates hypertension-induced inflammation/oxidative stress: support from Bartter's/Gitelman's patients. **Am J Hypertens.** 2010; 23:936
190. CALO' LA, Davis PA. Number and function of circulating endothelial progenitor cells and calcitonin gene-related peptide in hypertension: support from and opportunities in Bartter's and Gitelman's syndromes patients. **J Hypertens.** 2010; 28:2169-2170.
191. Syrén ML, Borsa Ghiringhelli N, Bettinelli A, Colussi G, Vargas-Poussou R, Tammaro F, Coviello DA, Tedeschi S and The Italian Collaborative Group for Gitelman Syndrome. The mutation c.1196_1202dup7bp (p.Ser402X) in the SLC12A3 gene clusters in Italian Gitelman syndrome patients and reflects the presence of a common ancestor. **Nephrol Dial Transplant.** 2011 26:557-561.
192. CALO' LA, Naso A, Davis PA, Pagnin E, Corradini R, Tommasi A, Sereni L, Ragazzi E. Hemodiafiltration With Online Regeneration of Ultrafiltrate: Effect on Heme-Oxygenase-1 and Inducible Subunit of Nitric Oxide Synthase and Implication for Oxidative Stress and Inflammation. **Artif Organs** 2011; 35:183-187.
193. Savica V, CALO' LA, Santoro D, Monardo P, Santoro G, Muraca U, Davis PA, Bellinghieri G. Salivary glands: a new player in phosphorus metabolism. **J Ren Nutr.** 2011; 21:39-42.
194. CALO' LA, Savica V, Piccoli A, Fusaro M, D'Angelo A, Davis PA. Reduction of Hyperphosphatemia is Related with the Reduction of C-Reactive Protein in Dialysis Patients. Study in Sevelamer-Resistant Dialysis Patients Treated with Chitosan Chewing Gum as Salivary Phosphate Binder. **Ren Fail.** 2011; 33:11-4.
195. CALO' LA, Naso A, D'Angelo A, Pagnin E, Zanardo M, Puato M, Rebeschini M, Ladini S, Feriani M, Perego A, Malagoli A, Zagatti R, Calzavara P, Cascone C, Davis PA. Molecular Biology Based Assessment of Vitamin E-Coated Dialyzer Effects on Oxidative Stress, Inflammation and Vascular Remodeling. **Artif Organs** 2011; 35:E33-39.
196. CALO' LA, Treatment with Vitamin E coated membrane dialysers and cardiovascular protection in dialysis patients. **Nephrol Dial Transplant.** 2011; 26:1754.
197. Fusaro M, Crepaldi G, Maggi S, Galli F, D'Angelo A, CALO' L, Giannini S, Miozzo D, Gallieni M. Vitamin K, bone fractures, and vascular calcifications in chronic kidney disease: an important but poorly studied relationship. **J Endocrinol Invest.** 2011; 34: 317-23.
198. Savica V, CALO' LA, Santoro D, Monardo P, Mallamace A, Bellinghieri G. Urine therapy through the centuries. **J Nephrol** 2011; 24 Suppl 17:S123-S125.
199. CALO' LA, Maso LD, Caielli P, Pagnin E, Fusaro M, Davis PA, Pessina AC. Effect of olmesartan on oxidative stress in hypertensive patients. Mechanistic support to clinical trials derived evidence. **Blood Press.** 2011; 20:362-369.
200. Fusaro M, Crepaldi G, Maggi S, D'Angelo A, CALO' L, Miozzo D, Fornasieri A, Gallieni M. Bleeding, Vertebral Fractures and Vascular Calcifications in Patients Treated with Warfarin: Hope for Lower Risks with Alternative Therapies. **Curr Vasc Pharmacol.** 2011; 9:763-769

201. Fusaro M, D'Angelo A, Naso A, Frigo AC, Miozzo D, Gallieni M, CALO' LA. Treatment with Calcimimetic (Cinacalcet) Alters Epoetin Dosage Requirements in Dialysis Patients: Preliminary Report. **Ren Fail**. 2011; 33:732-735.
202. CALO' LA, Bordin L, Davis PA, Pagnin E, Dal Maso L, Rossi GP, Pessina AC, Clari G. PLC β 1-SHP-2 complex, PLC β 1 tyrosine dephosphorylation and SHP-2 phosphatase activity: a new part of Angiotensin II signaling? **J Biomed Sci**. 2011; 18:38.
203. CALO' LA, Facco M, Davis PA, Pagnin E, Maso LD, Puato M, Caielli P, Agostini C, Pessina AC. Endothelial progenitor cells relationships with clinical and biochemical factors in a human model of blunted angiotensin II signaling. **Hypertens Res**. 2011; 34:1017-1022.
204. CALO' LA, Caielli P. Antihypertensive and antiremodeling effects of Rho kinase inhibition via activation of ACE2 pathway: support from studies in a human model opposite to hypertension. **J Hypertens** 2011; 29:1660-1.
205. CALO' LA. EPO and HO-1 in cardiovascular and renal protection: just a common signaling pathway or a mechanistic link? **Nephrol Dial Transplant** 2011; 26:3416-3417.
206. Caielli P, Pengo MF, Ragazzo F, Rossi GP, CALO' LA. Antiplatelets treatment in atherosclerotic renal artery stenosis: need of consensus-based recommendations. **J Hypertens**. 2011; 29:2279-2281.
207. CALO' LA, Davis PA, Pessina AC. Does p63RhoGEF, a new key mediator of angiotensin II signaling, play a role in blood pressure regulation and cardiovascular remodeling in humans? **J Renin Angiotensin Aldosterone Syst**. 2011;12:634-636.
208. CALO' LA, Caielli P. Gitelman's syndrome and pregnancy: new potential pathophysiological influencing factors, therapeutic approach and materno-fetal outcome. **J Mater-Fetal & Neonat Medic** 2011, 25:1511-1513.
209. Favero M, CALO' LA, Schiavon F, Punzi L. Bartter's and Gitelman's diseases. **Best Pract Res Clin Rheumatol**. 2011; 25:637-648.
210. Rossi GP, Seccia TM, Miotto D, Zucchetto P, Cecchin D, CALO' L, et al. The Medical and Endovascular Treatment of Atherosclerotic Renal Artery Stenosis (METRAS) study: rationale and study design. **J Hum Hypertens**. 2012; 26:507-516
211. Armanini D, CALO' L, Fiore C. Salt and aldosterone don't get along with each other: implication of mineralocorticoid receptors in the profibrotic action of aldosterone. **Kidney Int** 2012; 81:118.
212. Maniero C, Fassina A, Seccia TM, Toniato A, Iacobone M, Plebani M, De Caro R, CALO' LA, Pessina AC, Rossi GP. Mild hyperparathyroidism: a novel surgically correctable feature of primary aldosteronism. **J Hypertens**. 2012; 30:390-395.
213. CALO' LA, Savica V, Davis PA. Phosphate content of beverages in addition to food phosphate additives: real and insidious danger for renal patients. **J Ren Nutr** 2012; 22:292-293.
214. De Filippis V, Lancellotti S, Maset F, Spolaore B, Pozzi N, Gambaro G, Oggianu L, CALO' LA, De Cristofaro R. Oxidation of Met1606 in von Willebrand Factor is a Risk Factor for Thrombotic and Septic Complications in Chronic Renal Failure. **Biochem J** 2012; 442:423-432.
215. CALO' LA. Angiotensin II type 2 receptors mediating both vasoconstriction and vasodilation in humans: support from data in a human model of endogenous angiotensin II type 1 receptor antagonism. **J Hypertens**. 2012; 30:628-629.
216. CALO' LA, Vertolli U, Davis PA, Savica V. L carnitine in hemodialysis patients. **Hemodial Int**. 2012; 16:428-434

217. Vertolli U, CALO' LA, Naso A, Lupia M, Vezzaro R. Echocardiography might not be able to detect left ventricular hypertrophy in all dialysis patients. **Minerva Med.** 2012;103:141-142.
218. CALO' LA, Davis PA, Pagnin E, Dal Maso L, Caielli P, Rossi GP. Calcitonin gene-related peptide, heme oxygenase-1, endothelial progenitor cells and nitric oxide-dependent vasodilation relationships in a human model of angiotensin II type-1 receptor antagonism. **J Hypertens.** 2012; 30:1406-1413.
219. Rossi GP, Ragazzo F, Seccia TM, Maniero C, Barisa M, CALO' LA, Frigo AC, Fassina A, Pessina AC. Hyperparathyroidism Can Be Useful in the Identification of Primary Aldosteronism Due To Aldosterone-Producing Adenoma. **Hypertension.** 2012; 60:431-436.
220. CALO' LA, Davis PA. Magnesium and Gitelman's Syndrome - a paradox awaiting resolution. **Magnes Res.** 2012; 25:147-148.
221. CALO' LA, Caielli P, Maiolino G, Pessina AC, Paolo Rossi G. Revascularization for atherosclerotic renal artery stenosis: another flawed son of the ASTRAL Study. **Hypertens Res.** 2013; 36:85-86.
222. Vertolli U, Ruffatti A, De Giorgi ML, Scapin V, Naso A and CALO' LA. A very unusual case of hypokalaemia. **Clin Kidney J** 2013; 6: 87-89.
223. Rossi GP, Piccoli A, CALO' LA. Ultrafiltration in heart failure with cardiorenal syndrome. **N Engl J Med** 2013; 368:1157-1158.
224. Pengo MF, Soloni P, Cecchin D, Maiolino G, Rossi GP, CALO' LA. Pelvic-ureteric junction obstruction and hypertension with target organ damage: A case report and review of the literature. **Blood Press.** 2013; 22:336-339.
225. Maiolino G, CALO' LA. Angiotensin II type 1 and type 2 receptor interplay in hypertension: lesson from a human model of vascular hyporeactivity. **J Hypertens.** 2013; 31:1055-1056.
226. Fusaro M, Noale M, Tripepi G, Giannini S, D'Angelo A, Pica A, CALO' LA, Miozzo D, Gallieni M. Long-Term Proton Pump Inhibitor Use is Associated with Vascular Calcification in Chronic Kidney Disease: A Cross-Sectional Study Using Propensity Score Analysis. **Drug Saf.** 2013; 36:635-642. DOI 10.1007/s40264-013-0062-6
227. Davis PA, Pagnin E, Dal Maso L, Caielli P, Maiolino G, Fusaro M, Paolo Rossi G, CALO' LA. SIRT1, heme oxygenase-1 and NO-mediated vasodilation in a human model of endogenous angiotensin II type 1 receptor antagonism: implications for hypertension. **Hypertens Res.** 2013 36:873-878.
228. CALO' LA, Caielli P, Maiolino G, Rossi G. Arterial hypertension and cardiovascular risk in HIV-infected patients. **J Cardiovasc Med** (Hagerstown). 2013;14(8):553-558. doi: 10.2459/JCM.0b013e3283621f01.
229. Vertolli U, Davis PA, Dal Maso L, Maiolino G, Naso A, Plebani M, CALO' LA. Daily green tea extract supplementation reduces prothrombotic and inflammatory states in dialysis patients. **Journal of Functional Foods** 2013, 5:1366-1371 <http://dx.doi.org/10.1016/j.jff.2013.05.004>
230. CALO' LA, Davis PA, Rossi GP. On hypertension in Gitelman's syndrome. **Nephrol Dial Transplant** 2013 E-Letter published July 9, 2013
231. Rossi GP, CALO' LA, Maiolino G, Zoccali C. Ultrafiltration for the treatment of congestion: a window into the lung for a better caress to the heart. **Nephrol Dial Transplant.** 2013 Sep 5. [Epub ahead of print]. doi: 10.1093/ndt/gft371

232. Bisogni V, Rossi GP, CALÒ LA. Apparent mineralcorticoid excess syndrome, an often forgotten or unrecognized cause of hypokalemia and hypertension: Case report and appraisal of the pathophysiology. **Blood Press**. 2013; 23:189-192
233. Maiolino G, Rossitto G, Caielli P, Bisogni V, Rossi GP, CALÒ LA. The role of oxidized low-density lipoproteins in atherosclerosis: the myths and the facts. **Mediat Inflamm**. 2013;2013:714653. doi: 10.1155/2013/714653.
234. Savica V, Santoro D, Ricciardi B, Ricciardi CA, CALÒ LA, Bellinghieri G. Morbus dominorum: gout as the disease of lords. **J Nephrol** 2013; 26 (Suppl. 22):113-116.
235. CALÒ LA, D'Angelo A, Savica V, Marson P. De Lapidibus podagra et chiragra in humano corpore productis (Rome, 1699): the contribution of Giovanni Battista Contoli to the description and classification of urinary tract stones. **J Nephrol**. 2013; 26 (Suppl. 22):136-138.
236. Galletti F, Agabiti-Rosei E, Bernini G, Boero R, Desideri G, Fallo F, Mallamaci F, Morganti A, Castellano M, Nazzaro P, Trimarco B, Strazzullo P; MINISAL-GIRCSI Program Study Group. Excess dietary sodium and inadequate potassium intake by hypertensive patients in Italy: results of the MINISAL-SIIA study program. **J Hypertens** 2014; 32:48-56.
237. CALÒ LA, Vertolli U, Davis PA, Dal Maso L, Pagnin E, Ravarotto V, Maiolino G, Lupia M, Seccia TM, Rossi GP. Molecular biology based assessment of green tea effects on oxidative stress and cardiac remodelling in dialysis patients. **Clinical Nutrition** 2014; 33: 437-442 <http://dx.doi.org/10.1016/j.clnu.2013.06.010>
238. CALÒ LA, Dal Maso L, Pagnin E, Ravarotto V, Facco M, Boscaro E, Maiolino G, Pessina AC, Rossi GP. Effect of olmesartan medoxomil on number and survival of circulating endothelial progenitor cells and calcitonin gene related peptide in hypertensive patients. **J Hypertens** 2014; 32:193-199.
239. Vertolli U, Davis PA, CALÒ LA. Fractured catheter guide wire in the right ventricle of a dialysis patient. **Nephrology (Carlton)**. 2014; 19:61-62.
240. Vertolli U, Vinci C, Rebeschini M, Ruffatti A, Scaparrotta G, Napodano M, Naso A, CALÒ LA. "Of coronary arteries and men": the fight of a dialysis patient against his coronary arteries. **Ren Fail**. 2014; 36:627-630.
241. CALÒ LA, Davis PA. Treatment with hemodiafiltration and cardiovascular protection in dialysis patients. **Nephrol Dial Transplant** 2014; e-Letter published February 17, 2014.
242. CALÒ LA, Davis PA, Pagnin E, Dal Maso L, Maiolino G, Seccia TM, Pessina AC, Rossi GP. Increased level of p63RhoGEF and RhoA/Rho kinase activity in hypertensive patients. **J Hypertens** 2014; 32:331-338.
243. CALÒ LA, Maiolino G, Pagnin E, Vertolli U, Davis PA. Increased RBP4 in a human model of activated anti-atherosclerotic and antiremodelling defences. **Eur J Clin Invest** 2014; 44:567-572.
244. Vertolli U, Naso A, Rubini C, Carmello R, CALÒ LA. Hypokalemia in thyrotoxic periodic paralysis: implication for nephrology practice. **Blood Purif** 2014; 37:188.
245. CALÒ LA, Davis PA. Dissociating angiotensin 1-9 antihypertensive remodeling effects from those on blood pressure. **J Hypertens** 2014; 32:1718-1719.
246. CALÒ LA. Hemodiafiltration and reduction of inflammation in dialysis patients. **Kidney Int** 2014; 86:651.
247. CALÒ LA, Davis PA, Rossi GP. Understanding the mechanisms of angiotensin II signaling involved in hypertension and its long-term sequelae: insights from Bartter's and Gitelman's

- syndromes, human models of endogenous angiotensin II signaling antagonism. **J Hypertens** 2014; 32:2109-2119.
248. CALÒ LA, Lenzini L, Rossi GP. Aldosterone-induced oxidative stress: a potential mechanism of aldosterone autonomy in primary aldosteronism. **J Hypertens** 2014; 32:2280-2281.
249. Maiolino G, Naso E, CALÒ LA. Angiotensin II Type 2 Receptor Effects: Lesson From a Human Model of Vascular Hyporeactivity. Letter Regarding Kemp et al. **Circ Res** 2014; 115:e24-25.
250. Benetti E, De Giorgi ML, CALÒ LA. On the Association of High GFR with Cardiovascular-Renal Damage. **Blood Purif** 2014;38:108.
251. Pengo MF, Rossitto G, Bisogni V, Piazza D, Frigo AC, Seccia TM, Maiolino G, Rossi GP, Pessina AC, CALÒ LA. Systolic and diastolic short-term blood pressure variability and its determinants in patients with controlled and uncontrolled hypertension: A retrospective cohort study. **Blood Press**. 2015; 24:124-129
252. CALÒ LA, Maiolino G. Mechanistic approach to the pathophysiology of target organ damage in hypertension from studies in a human model with characteristics opposite to hypertension: Bartter's and Gitelman's syndromes. **J Endocrinol Invest**. 2015; 38:711-716.
253. Caielli P, Frigo AC, Pengo MF, Rossitto G, Maiolino G, Seccia TM, CALÒ LA, Miotto D, Rossi GP. Treatment of atherosclerotic renovascular hypertension: review of observational studies and a meta-analysis of randomized clinical trials. **Nephrol Dial Transplant** 2015; 30:541-553.
254. Ravarotto V, Pagnin E, Fragasso A, Maiolino G, CALÒ LA. Angiotensin II and Cardiovascular-Renal Remodelling in Hypertension: Insights from a Human Model Opposite to Hypertension. **High Blood Press Cardiovasc Prev**. 2015; 22:215-223.
255. Maiolino G, Azzolini M, Paolo Rossi G, Davis PA, CALÒ LA. Bartter's/Gitelman's Syndromes as a model to study systemic oxidative stress in humans. **Free Radic Bio Med**. 2015; 88(Pt A):51-58.
256. Naso A, Scaparrotta G, Naso E, CALÒ LA. Intensive Home Hemodialysis: An Eye at the Past Looking for the Hemodialysis of the Future. **Artif Organs**. 2015; 39:736-740.
257. CALÒ LA, Maiolino G, Naso A, Davis PA. The association of systemic oxidative stress with insulin resistance: mechanistic insights from studies in Bartter's and Gitelman's syndromes. **Clin Endocrinol (Oxf)**. 2015; 83(6):994-995.
258. CALÒ LA, Davis PA, Pagnin E, Maiolino G. Rho kinase, oxidative stress, ACE2/Ang 1-7 and lung fibrosis. **Minerva Med**. 2015; 106:182-183.
259. CALÒ LA, Maiolino G. Hypomagnesaemia, cardiovascular-renal negative effects and Gitelman's syndrome: A paradox awaiting resolution. **Int J Cardiol** 2015;198:106-107.
260. CALÒ LA, Savoia C, Davis PA, Pagnin E, Ravarotto V, Maiolino G. Relationship between NOX4 level and angiotensin II signaling in Gitelman's syndrome. Implications with hypertension. **Int J Clin Exp Med**. 2015; 8:7487-7496.
261. Seccia TM, Rossitto G, CALÒ LA, Rossi GP. Oral Burning With Dysphagia and Weight Loss. **Medicine (Baltimore)**. 2015; 94:e1163.
262. Ravarotto V, Pagnin E, Maiolino G, Fragasso A, Carraro G, Rossi B, CALÒ LA. The blocking of angiotensin II type 1 receptor and RhoA/Rho kinase activity in hypertensive patients: Effect of olmesartan medoxomil and implication with cardiovascular-renal remodeling. **J Renin Angiotensin Aldosterone Syst**. 2015; 16:1245-1250.

263. CALÒ LA, Maiolino G. NOX4: the good side of NADPH oxidase for cardiovascular system. Re: "Reactive Oxygen Species Can Provide Atheroprotection via NOX4-Dependent Inhibition of Inflammation and Vascular Remodeling" Gray, et al., ATVB AHA.115.307012doi:10.1161/ATVB AHA.115.307012 **ATVB** e-letter, 2016, January 4.
264. Savica V, Maiolino G, CALÒ LA. To reconsider (limit) the use of phosphate based food and beverages additives. A real need for health preservation. **Clin Nutr** 2016; 35:240
265. Maiolino G, Mareso S, Bisogni V, Rossitto G, Azzolini M, Cesari M, Seccia TM, CALÒ L, Rossi GP. Assessment of the Quantitative Value Usefulness of the Aldosterone-Renin Ratio (ARR) for Primary Aldosteronism (AQUARR) Study. **High Blood Press Cardiovasc Prev**. 2016; 23:19-23
266. CALÒ LA, Davis PA, Maiolino G, Pagnin E, Ravarotto V, Naso E, Carraro G, Naso A. Assessing the Relationship of Angiotensin II Type 1 Receptors with Erythropoietin in a Human Model of Endogenous Angiotensin II Type 1 Receptor Antagonism. **Cardiorenal Med**. 2016; 6:16-24.
267. CALÒ LA, Vertolli U, Pagnin E, Ravarotto V, Davis PA, Lupia M, Naso E, Maiolino G, Naso A. Increased rho kinase activity in mononuclear cells of dialysis and stage 3-4 chronic kidney disease patients with left ventricular hypertrophy: Cardiovascular risk implications. **Life Sci**. 2016;148:80-85.
268. Galletti F, Barbato A, Minisal-Gircsi Study Group. Prevalence and determinants of resistant hypertension in a sample of patients followed in Italian hypertension centers: results from the MINISAL-SIIA study program. **J Hum Hypertens**. 2016; 30:703-708
269. Maiolino G, Pagnin E, Plebani M, Davis PA, CALÒ LA. Uric acid and cardiovascular-renal disease risk. Insights from a human model opposite to hypertension. **Int J Cardiol**. 2016; 212:18-19.
270. Pagnin E, Maiolino G, CALÒ LA. Heme oxygenase-1 in type 2 diabetes: from cell first-line defense to early marker of diabetic nephropathy. **Minerva Med**. 2016;107:123-124.
271. Seccia TM, Caroccia B, Gioco F, Piazza M, Buccella V, Guidolin D, Guerzoni E, Montini B, Petrelli L, Pagnin E, Ravarotto V, Belloni AS, CALÒ LA, Rossi GP. Endothelin-1 Drives Epithelial-Mesenchymal Transition in Hypertensive Nephroangiosclerosis. **J Am Heart Assoc**. 2016 Jul 21; 5(7). pii: e003888. doi: 10.1161/JAHA.116.003888.
272. Blanchard A, Bockenbauer D, Bolignano D, CALÒ LA, Cosyns E, Devuyst O, Ellison DH, Karet Frankl FE, Knoers NV, Konrad M, Lin SH, Vargas-Poussou R. Gitelman syndrome: consensus and guidance from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. **Kidney Int** 2017;91:24-33.
273. Seccia TM, Caroccia B and CALÒ LA. Hypertensive nephropathy. Moving from classic to emerging pathogenetic mechanisms. **J Hypertens** 2017;35:205-212.
274. CALÒ LA, Maiolino G, Alessi M. Magnesium, cardiovascular-renal disease and the Gitelman's syndrome paradox. **J Hypertens** 2017; 35:1122-1124.
275. Maiolino G, CALÒ LA, Rossi GP. The Time has Come for Systematic Screening for Primary Aldosteronism in All Hypertensives. **J Am Coll Cardiol** 2017; 69:1821-1823.
276. Seccia TM, CALÒ LA. Endothelin-1-induced endothelial mesenchymal transition via endothelin type B receptor stimulation: implication for chronic kidney disease. **J Hypertens** 2017; 35:1329-1330.
277. Vertolli U, Alessi M, Naso E, Naso A, CALÒ LA. A Very Unique Case of Boric Acid Intoxication With Very High-magnitude Rhabdomyolysis. **Iran J Kidney Dis** 2017; 11:256-257.

278. CALÒ LA, Vertolli U, Naso E, Maiolino G. Is there an increased heme oxygenase-1 behind the antioxidant effects of green tea on blood pressure and sympathoexcitation reduction? **J Hypertens** 2017; 35:1718-1719.
279. Vertolli U, Malipiero G, Alessi M, Bonfante L, CALÒ LA. Thymoma-associated renal pathology: Is renal biopsy always necessary? A clinical problem-solving exercise and teaching example for physicians. **Int Urol Nephrol**. 2017; 49:1893-1895.
280. Pagnin E, Ravarotto V, Maiolino G, Naso E, Davis PA, CALÒ LA. Gaq/p63RhoGEF interaction in RhoA/Rho kinase signaling: investigation in Gitelman's syndrome and implications with hypertension. **J Endocrinol Invest**. 2017 doi: 10.1007/s40618-017-0749-0.
281. Fusaro M, Gallieni M, Aghi A, Iervasi G, Rizzo MA, Stucchi A, Noale M, Tripepi G, Nickolas T, Veronese N, Fabris F, Giannini S, CALÒ LA, Piccoli A, Mereu MC, Cosmai L, Ferraro A, Magonara F, Spinello M, Sella S, Plebani M. Cigarette smoking is associated with decreased Bone Gla-protein (BGP) levels in hemodialysis patients. **Curr Vasc Pharmacol**. 2017 Sep 19. doi: 10.2174/1570161115666170919182421.
282. CALÒ LA, Ravarotto V, Simioni F, Naso E, Marchini F, Bonfante L, Furian L, Rigotti P. Pathophysiology of Post Transplant Hypertension in Kidney Transplant: Focus on Calcineurin Inhibitors Induced Oxidative Stress and Renal Sodium Retention and Implications with RhoA/Rho Kinase Pathway. **Kidney Blood Press Res**. 2017; 42:676-685.
283. Pengo MF, Ioratti D, Bisogni V, Ravarotto V, Rossi B, Bonfante L, Simioni F, Nalesso F, Maiolino G, CALÒ LA. In Patients with Chronic Kidney Disease Short Term Blood Pressure Variability is Associated with the Presence and Severity of Sleep Disorders. **Kidney Blood Press Res** 2017; 42:804-815.
284. Menegolo M, Xodo A, Alessi M, Maturi C, Simioni F, Rossi B, CALÒ LA, Antonello M and Grego F. Elderly patient: which vascular access? Choice and management of vascular access in the elderly patient. **Nephrology @ Point of Care** 2018; 4: 1-5.
285. Seccia TM, CALÒ LA. Is exercise becoming a danger for our health? The complex relationship between exercise and atrial fibrillation. **Eur J Prev Cardiol** 2018; 25:621-623.
286. Menegolo M, Xodo A, Alessi M, Maturi C, Simioni F, CALÒ LA, Antonello M, Frego F. Elderly patient: which vascular access? Choice and management of vascular access in the elderly patient. **NEPHROLOGY@POINT OF CARE**; 2018, Handle: <http://hdl.handle.net/11577/3269869>.
287. CALÒ LA, Ravarotto V. Bartter's and Gitelman's syndromes. DOI:10.1016/B978-0-12-801238-3.65335-7. In **Encyclopedia of Endocrine Diseases** 2nd Edition 2018.
288. Ravarotto V, Loffing J, Loffing-Cueni D, Heidemeyer M, Pagnin E, CALÒ LA, Rossi GP. Gitelman's Syndrome: characterization of a novel c.1181G>A point mutation and functional classification of the known mutations. **Hypertens Res**. 2018 Jun 20. doi: 10.1038/s41440-018-0061-1. [Epub ahead of print]

**LAVORI PUBBLICATI SU ATTI DI CONGRESSI
INTERNAZIONALI.**

1. A.Tasca, CALO' L., P.Ferrarese, M.Fiorello, F.Zattoni, R.Castrignano, P.Benetollo, A.D'Angelo. Short-term effects of percutaneous nephrolithotomy on the kidney. **Mineral Metabolism Research in Italy**, vol.6, 89- 91, 1985. Proceedings of the 7th Meeting of the Italian Society of Mineral Metabolism. Wighting Ed., Milano.
2. CALO' L., S.Cantaro, A.Vianello, A.Antonello and A.Borsatti. Effect of Muzolimine on renal prostaglandin E2 synthesis and catabolism in rat kidney. **Diuretics: Basic, Pharmacological and Clinical Aspects**, Proceedings of the International Meeting on Diuretics (Sorrento, May 26-30, 1986), M.Nijhoff Publ., 1987, pag. 574-576.
3. CALO' L., S.Cantaro, G.Rouben, A.Antonello and A.Borsatti. Effect of Hydrochlorothiazide on prostaglandin E2 synthesis and catabolic rate in rat kidney. **Diuretics II: Chemistry, Pharmacology and Clinical Applications**. Proceedings of the Second International Conference on Diuretics (Cascais, June 22-27, 1986), J.B.Puschett Ed., Elsevier 1987.
4. CALO' L., S.Cantaro, F.Marchini, G.Gambaro, B.Baggio, A.D'Angelo, H.Williams and A.Borsatti. Prostaglandin E2, and hydrochlorothiazide- mediated hypocalciuria: a hypothesis. In: **Urolithiasis**, Edited by V.R.Walker, R.A.L.Sutton, E.C.B.Cameron and W.G.Robertson. Plenum Press, New York, 1989, pag.363-366.
5. S.Cantaro, F.Marchini, CALO' L., G.Gambaro, A.Piccoli, H.E.Williams, B.Baggio and A.Borsatti. Oxalate exchange in red blood cells of calcium-oxalate stone formers: a pharmacological study. In: **Urolithiasis**, Edited by V.R.Walker, R.A.L.Sutton, E.C.B.Cameron and W.G.Robertson. Plenum Press, New York, 1989, pag.443-445.
6. CALO' L., S.Cantaro, B.Baggio, A.D'Angelo, G.Bazzato and A.Borsatti. Hypocalciuric action of hydrochlorothiazide and PGE2. **Diuretics III: Chemistry, Pharmacology, and Clinical Applications**. Jules B.Puschett and Arthur Greenberg, Editors, Elsevier Science Publishing 1990.
7. M.Bortolami, F.De Lazzari, C.Venturi, CALO' L., D.Branca and R.Naccarato. Effect of ethanol on activated Kupffer cells. In: **Chronic liver damage. Excerpta Medica**, Amsterdam- New York- Oxford, 1990, pagg. 51-56.
8. S.Favaro, G.Meneghel, A.Giacomini, L.De Silvestro, CALO' L., L.Conventi, A.Borsatti. Characterization of tissue cell infiltrates in chronic pyelonephritis. **4th Bari Seminar in nephrology: " Tubulo- interstitial nephropaties "** **Kluwer Academic Publ. Eds.** Norwell, Ma, USA, 1991, pagg. 231-235.
9. T.R. Wandzilak, CALO' L., D.W. Bowyer, P.A. Davis, A. Borsatti and H.E. Williams. Oxalate uptake in a human intestinal epithelial cell line, CACO-2. In: **Urolithiasis 2**, Edited by R.Ryal et al., Plenum Press, New York, 1994, pp. 125-128.
10. A.Antonello, V.Bordin, L.Bonfante, CALO' L., M.Normanno, A.Borsatti, M.Grigio, L.Busetti, B.Permutti, G.Cardin, G.Saladini, D.Casara. La nefroangiofotoscintigrafia con tracciante ad estrazione glomerulare (^{99m}Tc -DTPA) e tubulare (^{99m}Tc -MAG 3) in corso di miocardiopatia dilatativa. In **Cardioneurology 3**, proceedings of the fifth European Meeting on Cardioneurology, Assisi, 6-8 Aprile 1995, pagg. 377-379.
11. R.Scognamiglio, CALO' L., M.Miorelli, S.Nistri, M.Palisi, F.Zerbo, M.Rizzolo, G.Fasoli, A.Borsatti. Myocardial dysfunction in Bartter's syndrome. In **Cardioneurology 3**, proceedings of the fifth European Meeting on Cardioneurology, Assisi, 6-8 Aprile 1995, pagg.357-358.
12. F.Schiavon, L.Punzi, M.Pianon, M.Michielotto, CALO' L., N.Bertazzolo, E.Rizzi, Gambari P.F. Comparison between the effects of simple arthrocentesis with and without 24 hours bed rest on synovial fluid PGE2 in rheumatoid arthritis. Proceedings of the **International conference on clinical biochemistry of physical exercise**, Padova 1-2/6/1995, pag. 45.

13. Gambaro G., Marchini F., Nassuato M.A., Nardellotto A., Checchetto S., CALO' L., B.Baggio. The hypercalciuric effect of PGE₂ in nephrolithiasic patients is mediated by inhibition of Na⁺-K⁺-2Cl⁻ cotransport activity. In **Renal Stones- aspects on their formation, removal and prevention**, Tiselius H.G. Ed., 1995, pagg. 95-98.
14. S.Cantaro, R.Marcon, CALO' L., S.Favaro and A.Borsatti. AE-1 activity in red blood cell of uremic patient. Proceedings of the **Second G.A. Borrelli Conference:Acid-base and electrolyte balance. Molecular, cellular and clinical aspects.** Capri July 8-9, 1995, N.G.De Santo and G.Capasso Eds., pagg.3-4.
15. Nobile L, CALO' L., Giannini S, Cantaro S, Carraro G, Vianello D, Tasca A, and D'Angelo A. Bone mineral density (BMD) and metabolism in patients with idiopathic hypercalciuria (IH) and recurrent calcium nephrolithiasis (RNC). In **Urolithiasis 1996**, edited by Pak CJ, Resnick MI, Preminger GM; Proceedings of the VIII International Symposium on Urolithiasis, Dallas, Tx, Sept 29th-Oct 2nd, 1996, pagg 488-489.
16. Scognamiglio R, Avogaro A, CALO' L., Fasoli G, Palisi M, Marin M, Dalla Volta S. The paradox of myocardial dysfunction in presence of a normal contractile reserve. Proceedings of the **III International Conference on Myocardial Function, Pathophysiological, methodological and clinical aspects**, Padova, October 23-25, 1996, pag. 33-34.
17. CALO' L., M.C. Bordin, S.Cantaro, M.Milani, L.Gandolfi, F.Zerbo, A.Antonello, S.Favaro, A.D'Angelo. Increased endothelial nitric oxide (ecNOS) pathway in Bartter's (BS) and Gitelman's (GS) syndrome contributes to their vascular hyporesponsiveness. In **Cardioneurology 4**, Proceedings of the fifth European Meeting on Cardioneurology, Assisi, 10-12 Aprile 1997, pagg. 235-236.
18. CALO' L., R.Marin, S.Cantaro, S.Zambon, M.Fusaro, A.Antonello, S.Favaro, A.D'Angelo and E.Manzato. Bartter's (BS) and Gitelman's (GS) patients' NO overproduction and LDL oxidation. Relationship to atherosclerosis. In **Cardioneurology 4**, Proceedings of the fifth European Meeting on Cardioneurology, Assisi, 10-12 Aprile 1997, pagg. 237-238.
19. S.Cantaro, CALO' L., A.D'Angelo. Cellular models for the study of progression of chronic renal failure. Proceedings of the **5th Taormina Course on Nephrology**, Eds F.Consolo, G.Bellinghieri, V.Savica, 1998, pagg. 115-117.
20. Milani M, Ceolotto G, Marcon R, Cantaro S, Bonfante L, Vianello D, Favaro S, D'Angelo A, Semplicini A and CALO' L. Abnormal cell signaling, reduced PKC, increased ecNOS and vascular hyporeactivity of Bartter's and Gitelman's syndromes. In **Cardioneurology 5**, Proceedings of the 7th Assisi European Meeting on Cardioneurology, Assisi, April 15-17, 1999, pagg. 229-231.
21. Milani M, Rigotti P, Livi U, Bonvicini P, Marcon R, Cantaro S, Zerbo F, D'Angelo A, Antonello A and CALO' L. Oxidative stress and nitric oxide system in the pathophysiology of post-transplant hypertension. In **Cardioneurology 5**, Proceedings of the 7th Assisi European Meeting on Cardioneurology, Assisi, April 15-17, 1999, pagg. 363-366.
22. CALO' L., S.Giannini, P.Bonvicini, S.Cantaro, L.Bonfante, R.Marcon, A.D'Angelo. iNOS, NO/O₂⁻ relationship and altered bone metabolism of idiopathic hypercalciuria (IH). In **"Kidney Stones"**, L.Borghesi, T.Meschi, A.Briganti, T.Schianchi, A.Novarini Eds, Proceedings **8th European Symposium on Urolithiasis**, Parma June 9-12, 1999, pagg.223-226.
23. A.Avogaro, CALO' L., F.Piarulli, S. de Kreutzenberg, C.Crepaldi, A.Tiengo, S.Del Prato. Endothelium and diabetes. Evidences for a relationship between metabolic control and inappropriate nitric oxide production. In: **Insulin Resistance, Metabolic Diseases and Diabetic Complications**, G.Crepaldi, A.Tiengo, S.Del Prato Eds., Elsevier, 1999, pagg. 91-97.
24. Pagnin E, Giacomini B, Huber W, Vianello D, Bonfante L, Semplicini A, Antonello A and CALO' L. Carvedilol reduces oxidative stress, fibrogenesis and blood pressure in kidney transplanted patients: a

- molecular biology approach. In **Cardioneurology 6**, Proceedings of the 8th Assisi European Meeting on Cardioneurology, Assisi, November 16-18, 2000, pagg. 295-297.
25. Pagnin E, Giacom B, Rigler P, Huber W, Semplicini A and CALO' L. Oxidative stress in CSA and FK-506 induced post-transplant hypertension. Effect of Ramipril. In **Cardioneurology 7**, Proceedings of the 8th Assisi European Meeting on Cardioneurology, Assisi, April 11-13, 2002, pagg. 397-399.
 26. CALO' L, Pagnin E, Stanic L, Munaretto G, Landini S, Fusaro M, Semplicini A, Piccoli A. Effect of epoetin on oxidative stress in hemodialysis. A molecular biologic approach. In **Cardioneurology 7**, Proceedings of the 8th Assisi European Meeting on Cardioneurology, Assisi, April 11-13, 2002, pagg. 431-433.
 27. Pagnin E, CALO' LA. Angiotensin II long-term signaling in Bartter's/Gitelman's syndrome. Relevance for hypertension and cardiovascular remodeling. In **Cardioneurology 8**, Proceedings of the 10th Assisi European Meeting on Cardioneurology, Assisi, April 1-3, 2004, pagg. 219-222.
 28. CALO' LA, Pagnin E, Montisci R, Ruscazio A, Semplicini A, Pessina AC. Cardiac dysfunction in Bartter's and Gitelman's syndrome. In **Cardioneurology 9**, Proceedings of the 11th Assisi European Meeting on Cardioneurology, Assisi, April 7-9, 2005, pagg. 259-262.

**LAVORI PUBBLICATI SU RIVISTE NAZIONALI E SU ATTI DI
CONGRESSI NAZIONALI.**

1. Baggio, S.Cantaro, CALO' L., C.Tessarini, S.Favaro, A.Borsatti. Valore diagnostico dell'escrezione urinaria dell' "angiotensin converting enzyme " in alcune nefropatie. LAB 8, 5-7, 1981.
2. A.Borsatti, S.Favaro, E.Ossi, B.Baggio, CALO' L., C.Tessarini, L.Conventi. La diagnostica di laboratorio delle nefriti interstiziali. Attualità nefrologiche e dialitiche, Il Pensiero scientifico Ed., 7-9 Dicembre 1979, pag. 59-68.
3. L.CALO', S.Cantaro, L.Bertazzo, O.Oliva, A.Piccoli, S.Eavaro, B.Baggio, A.Borsatti. La concentrazione eritrocitaria di fosfolipasi A2 nella ipertensione arteriosa essenziale umana. Nefrologia, Dialisi, Trapianti. Ed. Wichting, Milano 1981, pag.143-144.
4. C.Tessarini, S.Cantaro, CALO' L., A.Piccoli, O.Oliva, S.Favaro, B.Baggio, A.Borsatti. L'escrezione urinaria di alcuni mediatori dell'infiammazione nella glomerulonefrite con funzione renale integra. Giorn. Veneto di Scienze Mediche, 34, 37-39, 1983.
5. R.Cerutti, A.Piccoli, T.Fede, P.Camani, A.Avogadro, G.Nardo, CALO' L. Comportamento di alcuni parametri della funzionalità renale in periodo premenstruale (Na, K, P, Aldosterone, Callicreina). Ginec.Clin., IV, 3, 284-286, 1983.
6. G.P.Rossi, A.C.Pessina, A.Semplicini, S.Cantaro, CALO' L., A.Borsatti. Azione ipotensiva del Captopril: evidenza a favore di meccanismi diversi nell'ipertensione renale e reno-vascolare. Farmaci, vol.8, suppl. 2:1-9, 1984.
7. CALO' L., S.Cantaro, A.Piccoli, A.Vianello, C.Bardini, A.Bonadonna, A.Borsatti, A.Antonello. Interazioni tra Muzolimina, Prostaglandine e sistema Renina Angiotensina nel ratto. Basi Raz. Ter. IS, 77-78, 1985.
8. L.Punzi, F.Schiavon, L.CALO', S.Cantaro, A.Mazzi, S.Todesco. Effetto del Diclofenac sodico e della Indometacina sulle PGE2 e sui Nucleotidi ciclici del liquido sinoviale nell'artrite reumatoide. Basi Raz. Ter. 15, 105-106, 1985.
9. CALO' L., S.Cantaro, A.Piccoli, A.Vianello, A.Borsatti, R.Bardini, A.Antonello. Interazioni tra Muzolimina, PGE2 e sistema Renina- Angiotensina-Aldosterone nel ratto. Il Progresso Medico XLI n.4, 249-252, 1985.
10. L.Rossaro, A.Martin, G.C.Sturniolo, CALO' L., A.Borsatti, R.Naccarato. Canrenoato di potassio e Spironolattone nel trattamento dell'ascite. Atti del Convegno su: Canrenoato di potassio in epatologia, Milano, 20 Settembre 1985, pag. 103-109.
11. CALO' L., A.Vianello, S.Cantaro, A.Borsatti, E. Fiaschi. Prostaglandine, Trombossani e rene. Basi Raz. Ter., XVI, 15-22, 1986.
12. S.Todesco, L.Punzi, F.Schiavon, A.Mazzi, L.CALO', V.Malatesta, R.Ramonda, F.Marson, P.F.Gambari. Valutazione dei parametri clinici e biologici nelle reumatoartropatie algogene con e senza trattamento farmacologico. Sottoprogetto SP 8: Controllo del dolore. Obiettivo: 80. Consiglio Nazionale delle Ricerche, progetto finalizzato "Medicina preventiva e riabilitativa", pag. 181-183, Roma 17-21 Marzo, 1986.
13. CALO' L., S.Cantaro, G.Rouben. Ruolo dei diuretici tiazidici nell'omeostasi renale del calcio: studio in vitro. Medicina, 6, 375-376, 1986.
14. A.Piccoli, CALO' L., S.Cantaro, F.Modena, A.Antonello, A.Borsatti. La Prostaciclina è un mediatore importante della riserva funzionale renale. Nefrologia '87: Atti del XXVIII Congr. Soc. It. Nefrologia, Torino 1987, Acta Medica Edizioni & Congressi, 1987, pag. 127-128.

15. CALO' L. Ruolo dell'inibizione prostaglandinica sull'azione antiipercalcemica dell'idroclorotiazide: una possibile ipotesi. *Medicina*, 8: 432-434, 1988.
16. CALO' L., S.Cantaro, F.Marchini, G.Gambaro, B.Baggio, A.D'Angelo e A.Borsatti. L'effetto ipocalcemico dell'idroclorotiazide è mediato dalla inibizione della PGE₂ ? Atti del XXIX Congresso della Società Italiana di Nefrologia: *Nefrologia, Dialisi, Trapianto*, Wichtig Ed. Milano 1988, pag.315-318.
17. A.Borsatti, L.CALO', S.Cantaro. Escrezione di prostanoide nelle urine in corso di trattamento con enalapril. Atti del Congresso: Recenti acquisizioni nella terapia dell'ipertensione arteriosa. Firenze, 3-4 Dicembre 1988. Ed. A. Zanchetti, pag. 67-69.
18. CALO' L., S.Cantaro, B.Baggio, A.D'Angelo, M.Plebani, A.Borsatti. La inibizione della sintesi di PGE₂ potrebbe mediare l'effetto ipocalcemico dell'idroclorotiazide. Atti del 30° Congresso Nazionale della Società Italiana di Nefrologia, Venezia, 22-26 Maggio 1989, *Aula Medica* 1989, Vol.II, n.3-4, pag.1189-1192.
19. A.Tasca, F.Zattoni, P.Ferrarese, A.D'Angelo, CALO' L., F.Bui, P.Cagnato. Gli effetti a breve termine e stabilizzati della nefrolitotomia percutanea. *Acta Urol. Ital.* 4: 269-271, 1989.
20. S.Favaro, CALO' L., A.Borsatti Nuove prospettive di impiego dei radiofarmaci nelle nefropatie parenchimali bilaterali. Atti del V Corso di Aggiornamento professionale in Medicina Nucleare.*Nefro-Urologia*.Castello di Garganza, Aprile-Settembre 1990, pag.449-458.
21. F.Antonucci, M.Bertolissi, A.De Monte, M.Travaglini, O.Geatti, R.Franzon, CALO' L., S.Cantaro. Effetto dell'infusione continua di BAYa 1040 (Nifedipina) sulla funzione renale intraoperatoria dei pazienti sottoposti a chirurgia dell'aorta sottorenale. Atti del XXXI Congresso della Società Italiana di Nefrologia: *Nefrologia, Dialisi, Trapianto*, Wichtig Ed. Milano, 1990, Vol. II, pp. 935- 937.
22. S.Cantaro, CALO' L., A.Piccoli, F.Di Virgilio , S.Favaro, A.Borsatti. Ridotta produzione di IP₃ fMLP-indotta nella Sindrome di Bartter. *Ibidem* pagg.1181-1184.
23. CALO' L., A.Borsatti. Alcool ed Ipertensione arteriosa. In: *Sobrieta' e cultura*, a cura di M.Rambaldi et al., Editrice Compositori, Bologna,1991, pp.201-206.
24. F.Antonucci, M.Bertolissi, F.Giordano, A.De Monte, M.Travaglini, L.Conte, O.Geatti, S.Mazzolini, E.Scarsini e CALO' L. Endotelina plasmatica e funzione renale durante clampaggio aortico sottorenale: effetto dell'infusione intraoperatoria di dopamina e nifedipina. Atti del 32° Congresso Nazionale della Società Italiana di Nefrologia, Bologna 29 Maggio- 1 Giugno 1991, pag. 509-513.
25. N.G.De Santo, CALO' L., P.Anastasio, S.Coppola, S.Cantaro, S.Favaro, A.Capasso, A.Siciliano e A.Borsatti. La sintesi di prostaglandine non è in nesso causale con la genesi della risposta renale iperfiltrante al carico proteico acuto. *Ibidem*, pag.423-426.
26. P.Anastasio, N.G.De Santo, CALO' L., S.Coppola, S.Cantaro, S.Favaro, G.Capasso e A.Borsatti. PGE₂, PGF_{1a} e TxA₂ non hanno un ruolo nella modulazione della risposta iperfiltrante ad un carico proteico acuto nelle glomerulopatie umane primitive croniche con insufficienza renale. *Ibidem*, pag. 381-384.
27. CALO' L., S.Cantaro, G.Gambaro, F.Marchini, A.Piccoli, G.Cavatton, S.Favaro e A.Borsatti. Anomalie nella produzione granulocitaria di IP₃ nella nefrolitiasi calcio ossalica idiopatica. *Ibidem*, pag. 339-342.

28. CALO' L., A.D'Angelo, S.Favaro, A.Borsatti. Terapia antiipertensiva e dialisi. In: Secondo Meeting Nazionale Sassari 1994. Corso di Aggiornamento in Nefrologia-Dialisi-Trapianto. Sassari-Porto Conte 9-10 Settembre 1994; Ed. V.Bonomini, G.Sorba, pagg.95-99.
29. CALO' L., R.Scognamiglio, S.Nistri, M.Palisi, M.Marin, F.Zerbo, S.Favaro, M.Rizzolo, S.Cantaro, G.Fasoli, A.Borsatti, A.D'Angelo. Difetto del reclutamento contrattile calcio-dipendente nella Sindrome di Bartter. Ibidem, pagg. 111-115.
30. CALO' L., S.Favaro, A.Borsatti. Il trattamento dell'ipertensione arteriosa in dialisi. Atti del XXI Simposio Nefrologico Veneziano, Venezia, 19-3-1995, pag.95-99.
31. M. Rizzolo, CALO' L., S. Cantaro, M.C. Bordin, F. Zerbo, A. Brunello, L.Bonfante, P.Carraro, A. D'Angelo. Concentrazione urinaria di NO_2^- e NO_3^- , metaboliti dell'ossido nitrico, nella sindrome di Bartter. Le Basi Razionali della Terapia, XXVI n. 2:119-123, 1996.
32. CALO' L., A.Antonello, A.D'Angelo. Fattori di origine endoteliale ed ipertensione essenziale. Atti del XII Congresso della Società Triveneta di Nefrologia, Bolzano, 10-11 Ottobre 1996, pagg. 28-30.
33. L.Bonfante, A.D'Angelo, S.Favaro, A.Giacomini, M.Normanno, CALO' L., A.Antonello, V.Bordin, D.Vianello, A.Meani, A.Borsatti. Follow up di 7 anni (1987-1994) su una popolazione con microematuria persistente asintomatica e funzione renale integra. Minerva Medica, vol 87: 525-529, 1996.
34. CALO' L., S.Cantaro, F.Zerbo, L.Bonfante, M.Fusaro, L.Maldini, S.Favaro, A.Antonello, A.D'Angelo, M.Ferrari. Ruolo dei fattori vasoattivi di origine endoteliale nella patogenesi dell'ipertensione essenziale. Valutazioni fisiopatologiche e terapeutiche. Basi Raz. Ter., Vol. XXVII, 1: 29-36, 1997.
35. L.Bonfante, A.Rossi, A.D'Angelo con la collaborazione di A.Antonello, CALO' L., et al. Insufficienza renale cronica e danno carotideo. Giornale di tecniche nefrologiche e dialitiche, IX n.1:5-13, 1997.
36. CALO' L., Gandolfi L., Milani M., Rigotti P., Cantaro S., Marchini F., Bonfante L., D'Angelo A., Antonello A. Aumentata espressione genica della sintasi costitutiva dell'ossido nitrico in pazienti con trapianto di rene in trattamento con CsA. Relazione con l'ipertensione CsA-indotta. Atti del XXIV Congresso Nazionale della Società Italiana Trapianti d'Organo, Roma 2-4 Ottobre 1997, pagg. N21-N22.
37. A.D'Angelo, P.A.Ostuni, CALO' L., S.Cantaro, A.Ianniello, P.F.Gambari. Impegno renale nella sindrome di Sjogren primitiva. Atti del 6° Seminario Veronese di Nefrologia, Verona 20-21 Settembre 1996, Witching ed., 1997, pagg.53-57.
38. CALO' L., Cantaro S, Bonfante L, Favaro S, Antonello A, D'Angelo A. La determinazione della funzionalità renale: il punto di vista del nefrologo. Le Basi Razionali della Terapia, Vol XXVII n. 3-4:237-240, 1997.
39. L.Gesualdo, E.Ranieri, G.Grandaliano, F.P.Schena, F.Anglani, CALO' L., S.Cantaro, G.Gambaro, A.Borsatti. L'applicazione delle tecniche di PCR in biologia cellulare e istopatologia renale: potenzialità e limiti. Giornale Italiano di Nefrologia, 15: 297-306, 1998.
40. CALO' L. Radicali liberi, superossidi e stress ossidativo nella patogenesi e fisiopatologia dell'ipertensione arteriosa e delle sue complicanze. Current Therapeutics, Febbraio 1999, pagg. 1-8.

41. CALO' L, M.Milani, G.Ceolotto, R.Marcon, S.Cantaro, A.D'Angelo, A.Semplicini. Anomalia del signaling cellulare, riduzione della PKC, aumento di ecNOS mRNA e iporeattività vascolare nella sindrome di Bartter e di Gitelman. In Nefrologia, Dialisi e Trapianto, Atti del Congresso della Società Italiana di Nefrologia, Perugia, 16-19/6/1999, pagg.95-98.
42. S.Cantaro, F.Nalesso, R.Luciani, CALO' L, L.Bonfante, A.Meani, A.D'Angelo. Rapida down-regulation dell'espressione genica dei recettori AT1 e AT2 a opera dell'angiotensina 2[^] in cellule mesangiali umane in coltura primaria. Ibidem, pagg.223-224.
43. CALO' L, S.Giannini, L.Bonfante, R.Marcon, S.Cantaro, A.Antonello, A.D'Angelo. Ruolo dell'interrelazione tra superossidi e sistema dell'ossido nitrico nella fisiopatologia dell'iperparatiroidismo idiopatico (IH). Ibidem, pagg. 275-278.
44. CALO' L. L'Ipertensione arteriosa nel trapianto renale. In Nefroprotezione e prevenzione cardiovascolare nel nefropatico. La Lettera della Ipertensione, 2:3-7, 1999.
45. CALO' L, Marcon R, Pagnin E, Mennella G, Spinello M, Virgilio B, Cara M, Bonfante L, Antonello A. Il ruolo del sistema del monossido di azoto nell'ipertensione indotta da ciclosporina. Studio nel trapianto di rene. Basi Razionali della Terapia, 29(4):161-164, 1999.
46. A. Semplicini, CALO' L. I diuretici nel trattamento dell'ipertensione arteriosa. In: Le basi razionali dell'uso dei diuretici in medicina interna. Padova, 8-9 Giugno 2000, pp. 99-105.
47. Pagnin E, Giacon B, Zaghetto F, Vianello D, Bonfante L, Huber W, Antonello A, Semplicini A, CALO' L. Ipertensione arteriosa e stress ossidativo indotti dalla ciclosporina. Effetto del carvedilolo. Ann Ital Med Int 16:101-105, 2001
48. A. Semplicini, M.Sartori, A.Maresca, CALO' L. Scambi ionici transmembrana nell'ipertensione arteriosa: quale ruolo nel nuovo millennio? Ipertensione & Prevenzione Cardiovascolare, 6 n.1:25-28, 2001.
49. Semplicini A, Maresca A, CALO' L. Il trattamento farmacologico dell'ipertensione arteriosa da trattamenti immunosoppressivi nei trapianti di organi solidi. Atti del convegno "Fisiopatologia e terapia delle alterazioni circolatorie in medicina interna". Padova 31/5-1-6, 2001
50. Semplicini A, Ciccariello L, Mascagna V, De Mozzi P e CALO' L. Diuretici ed ACE inibitori: sinergie e contrasti. "I farmaci vasoattivi in Medicina Interna", Padova 27-28/6, 2002, pag 109-120.
51. Antonello A, Rippa Bonati M, D'Angelo A, Gambaro G, CALO' L, Bonfante L. Gout and kidney during XVII and XIX centuries. Reumatismo, 54(2):165-171. 2002
52. CALO' LA, Pessina AC. Il danno renale nell'ipertensione arteriosa. Ipertensione e prev cardiovasc. 11:78-80, 2004
53. Semplicini A, Ciccariello L, Mascagna V, Sartori M, CALO' L. ACE inibitori o antagonisti dell'angiotensina II nel paziente con diabete tipo 2? Atti del Simposio Attualità nella terapia dell'ipertensione nel diabete, 19° Congresso Nazionale della Società Italiana di Diabetologia, Verona 22 Maggio 2002, Il Diabete, Kurtis Editore 2003, pp 166-174
54. Sartori M, Parotto E, Ceolotto G, Papparella I, Lenzini L, CALO' LA, Semplicini A. [G-protein beta3-subunit gene 825T allele and cardiovascular risk] Ann Ital Med Int; 19:240-248, 2004
55. CALO' LA, Cosentino F, De Luca N. Metabolic syndrome: current issues and perspectives. Minerva Med. 2006 Feb; 97(1):1-3.

56. CALO' LA, Bertipaglia L, Pagnin E. Antioxidants, carnitine and erythropoietin. *G Ital Nefrol.* 2006 Jan-Feb;23 Suppl 4:S47-50.
57. CALO' LA. Impact of metabolic syndrome on chronic kidney disease. *Minerva Med.* 2006, 97:451-459.
58. P. Caielli, A.C. Frigo, M.F. Pengo, F. Ragazzo, L.A. CALO', G.P. Rossi. Trattamento medico o endovascolare nell'ipertensione nefrovascolare aterosclerotica? Risultati di una meta-analisi degli studi clinici randomizzati di confronto. *The Cardiorenal Journal* 2011; 17-26.
59. CALO' LA. Terapia di combinazione e protezione renale nell'ipertensione arteriosa. *Medicinae Doctor XXII*, 2015; 3:42-45.
60. CALO' LA, Naso E. I diuretici nell'Ipertensione: sono tutti uguali?. *Atti del Simposio: Prevenzione Cardiovascolare. XXII Brixen Conference*, Editor GP Rossi, Padova University Press, 2016, pag g. 117-123.
61. Caielli P, CALO' LA. I trials clinici randomizzati nella stenosiateroscleroticadelle arterie renali. *Atti del Simposio: Prevenzione Cardiovascolare. XXIII Brixen Conference*, Editors GP Rossi, AC Pessina, Padova University Press, 2017

MONOGRAFIE E CAPITOLI SU TRATTATI

Monografie

L.CALO', A. SEMPLICINI, "L'endotelio vascolare. Aspetti morfofunzionali, fisiopatologici e terapeutici". Piccin Editore, 1998.

CALO' L (1999). Radicali liberi, superossidi e stress ossidativo nella patogenesi e fisiopatologia dell'ipertensione arteriosa e delle sue complicanze. CURRENT THERAPEUTICS p. 1-8

Cosentino F, CALO' LA, De Luca N. La Sindrome Metabolica. Il Pensiero Scientifico Editore, 2006.

Capitoli su Trattati

L. CALO' in:" L'Annuario dei farmaci " a cura di E.Casiglia e R.Gava, Piccin Nuova Libreria Ed., Padova 1991, pagg. 15-22.

L. CALO' in:" L'Annuario dei farmaci " a cura di E.Casiglia e R.Gava, Piccin Nuova Libreria Ed., Padova 1991, pagg. 793-794.

A.AVOGARO, CALÒ LA., F.PIARULLI, S. DE KREUTZENBERG, C.CREPALDI, A.TIENGO, S.DEL PRATO. (1999). Endothelium and diabetes. Evidences for a relationship between metabolic control and inappropriate nitric oxide production. In: CREPALDI G, TIENGO A, DEL PRATO S. Insulin Resistance, Metabolic Diseases and Diabetic Complications. p. 91-97

CALO' L, Borsatti A (1991). Alcool ed Iperensione arteriosa.. In: Sobrietà e cultura. p. 201-206, BOLOGNA:Editrice Compositori.

Meani A., CALO' L. IL RENE, in De Palo E.F.: "Medicina di Laboratorio. Dalla biochimica all'applicazione diagnostica, Vol. I, Rosini Editrice Srl, Firenze, 1998, pagg. 232-245.

CALO' L, Meani A. IL RENE, in De Palo E.F.: "Medicina di Laboratorio. Dalla biochimica all'applicazione diagnostica, Vol. II, Rosini Editrice Srl, Firenze, 1998.

Semplicini A, Sartori M and CALO' L. Acute pulmonary oedema, renal insufficiency, and refractory hypertension. In "Cardiovascular clinical cases. Specific treatment strategies". Messerly FH, Hansson L, Mancina g, Ritz E Ed, 2002, pagg. 80-85.

Antonello A, CALO' L, Favaro S. "Nefropatie tubulo interstiziali" in: Trattato di Medicina Interna, G. Crepaldi, A. Baritussio, Volume III, Piccin Editore, 2003.

Cantaro S, Antonello A, CALO' L : "Nefropatie Vascolari", in: Trattato di Medicina Interna, G. Crepaldi, A. Baritussio, Volume III, Piccin Editore, 2003.

CALO' L. Il paziente iperteso nefropatico. In Gestione del paziente iperteso nella pratica clinica. Edizioni Minerva medica, pag 55-63, 2003

CALO' L, Veglio F. Il ruolo della terapia di combinazione nell'acquisizione degli obiettivi terapeutici: i risultati dei grandi trials. In Obiettivi terapeutici & Prevenzione Cardiovascolare: Il ruolo della terapia di associazione nel trattamento dell'ipertensione arteriosa. Editore Claudio Borghi, Edizioni Mediserve 2004, pag 47-52.

Elisa Pagnin and CALO' LA. Post-transplant hypertension and oxidative stress. Effect of different antihypertensive treatments. In Trends in RNA research. PA MacNamara Editor. Nova publishing, New York. 2006, pagg 121-144.

Pagnin E, Avogaro A, CALO' LA. Hypertension, diabetes, oxidative stress and cardiovascular remodeling: making the connection with p66shc. In: Oxidants in Biology. A question of balance; Valacchi G and Davis PA Eds, Springer, Germany, 2008, pp. 278-290.